CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CIRRHOSIS
HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS) THROMBOCYTOPENIA
NASH
CHOLESTATIC
PRIMARY BILIARY CHOLANGITIS (PBC)
HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Board of Advisors/Faculty 2022 GI Fellow Board of Advisors CLDF Committees
Centers of Educational Expertise  
Live Events Slide Library Webcasts Abstract Library Committee Members Conference Highlights
 
NASH | Abstract Library
Abstract Library
 
The summaries are free for public use. The Chronic Liver Disease Foundation will continue to add and archive summaries of articles deemed relevant to CLDF by the Board of Trustees and its Advisors.
1.Treatment Candidacy for Pharmacologic Therapies for NASH
 

Clin Gastroenterol Hepatol. 2022 Jun;20(6):1209-1217.doi: 10.1016/j.cgh.2021.03.005. Epub 2021 Mar 10.

Ian A Rowe 1, Vincent Wai-Sun Wong 2, Rohit Loomba 3
 
2.NAFLD in normal weight individuals
 

Diabetol Metab Syndr. 2022 Mar 24;14(1):45. doi: 10.1186/s13098-022-00814-z.

Johanna K DiStefano 1, Glenn S Gerhard 2
 
3.A new perspective on NAFLD: Focusing on lipid droplets
 

J Hepatol. 2022 Apr;76(4):934-945. doi: 10.1016/j.jhep.2021.11.009.Epub 2021 Nov 15.

Eleonora Scorletti 1, Rotonya M Carr 2
 
4.Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD
 

Nat Rev Endocrinol. 2022 Jan;18(1):55-66. doi: 10.1038/s41574-021-00584-0.Epub 2021 Nov 23.

Nobuharu Tamaki 1 2, Veeral Ajmera 1, Rohit Loomba 3 4
 
5.Fatty Liver Disease: Diagnosis and Stratification
 

Annu Rev Med. 2022 Jan 27;73:529-544.doi: 10.1146/annurev-med-042220-020407. Epub 2021 Nov 22.

Yedidya Saiman 1, Andres Duarte-Rojo 2, Mary E Rinella 3
 
6.Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease
 

Hepatology. 2021 Nov 15. doi: 10.1002/hep.32244. Online ahead of print.

Jennifer R Kramer 1 2, Yamini Natarajan 1 3, Jianliang Dai 4, Xian Yu 1, Liang Li 4, Hashem B El-Serag 3, Fasiha Kanwal 1 3
 
7.Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
 

Gastroenterology. 2021 Nov;161(5):1657-1669. doi: 10.1053/j.gastro.2021.07.049.Epub 2021 Sep 20.

Fasiha Kanwal 1, Jay H Shubrook 2, Leon A Adams 3, Kim Pfotenhauer 4, Vincent Wai-Sun Wong 5, Eugene Wright 6, Manal F Abdelmalek 6, Stephen A Harrison 7, Rohit Loomba 8, Christos S Mantzoros 9, Elisabetta Bugianesi 10, Robert H Eckel 11, Lee M Kaplan 12, Hashem B El-Serag 1, Kenneth Cusi 13
 
8.A Specifically Tailored Multistrain Probiotic and Micronutrient Mixture Affects Nonalcoholic Fatty Liver Disease-Related Markers in Patients with Obesity after Mini Gastric Bypass Surgery
 

J Nutr. 2022 Feb 8;152(2):408-418. doi: 10.1093/jn/nxab392.

Silke Crommen 1, Karl Peter Rheinwalt 2, Andreas Plamper 2, Marie-Christine Simon 3, Daniela Rösler 4, Rolf Fimmers 5, Sarah Egert 1 6, Christine Metzner 4 7
 
9.Obesity and Nonalcoholic Fatty Liver Disease
 

Nurs Clin North Am. 2021 Dec;56(4):543-552. doi: 10.1016/j.cnur.2021.07.009.

Amanda Chaney 1
 
10.What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?
 

Hepatol Commun. 2021 Nov;5(11):1810-1823. doi: 10.1002/hep4.1814.Epub 2021 Sep 9.

Naim Alkhouri # 1, Monica Tincopa # 2, Rohit Loomba # 3, Stephen A Harrison # 4 5
 
11.Role of Cholesterol-Associated Steatohepatitis in the Development of NASH
 

Hepatol Commun. 2022 Jan;6(1):12-35. doi: 10.1002/hep4.1801. Epub 2021 Aug 24.

Christian L Horn 1, Amilcar L Morales 1, Christopher Savard 2 3 4, Geoffrey C Farrell 5, George N Ioannou 2 3 4
 
12.Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms
 

PLoS One. 2022 Apr 15;17(4):e0266859.doi: 10.1371/journal.pone.0266859. eCollection 2022.

Tinsay A Woreta 1, Mark L Van Natta 2, Mariana Lazo 3, Arunkumar Krishnan 1, Brent A Neuschwander-Tetri 4, Rohit Loomba 5, Anna Mae Diehl 6, Manal F Abdelmalek 6, Naga Chalasani 7, Samer Gawrieh 7, Srinivasan Dasarathy 8, Raj Vuppalanchi 7, Mohammad S Siddiqui 9, Kris V Kowdley 10, Arthur McCullough 8, Norah A Terrault 11, Cynthia Behling 5, David E Kleiner 12, Mark Fishbein 13, Paula Hertel 14, Laura A Wilson 2, Emily P Mitchell 2, Laura A Miriel 2, Jeanne M Clark 1, James Tonascia 2, Arun J Sanyal 9, NASH Clinical Research Network
 
13.Efficacy of elafibranor in patients with liver abnormalities especially non-alcoholic steatohepatitis: a systematic review and meta-analysis
 

Clin J Gastroenterol. 2021 Dec;14(6):1579-1586. doi: 10.1007/s12328-021-01491-7.Epub 2021 Aug 9.

Adnan Malik 1, Mahum Nadeem 2, Muhammad Imran Malik 3
 
14.Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD
 

Gastroenterol. 2022 May;57(5):357-371.doi: 10.1007/s00535-022-01860-0. Epub 2022 Mar 24.

Javier Ampuero # 1 2 3, Rocío Gallego-Durán # 4 5, Douglas Maya-Miles 4 5, Rocío Montero 4 5, Sheila Gato 4 5, Ángela Rojas 4 5, Antonio Gil 4 5, Rocío Muñoz 4 5, Manuel Romero-Gómez 6 4 5
 
15.Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review
 

Semin Liver Dis. 2021 Nov;41(4):435-447. doi: 10.1055/s-0041-1731704.Epub 2021 Jul 9.

Anas Hashem 1, Amani Khalouf 1, Andres Acosta 1
 
16.The Effect of High-intensity Interval Training vs Moderate-intensity Continuous Training on Liver Fat: A Systematic Review and Meta-Analysis
 

J Clin Endocrinol Metab. 2022 Feb 17;107(3):862-881.doi: 10.1210/clinem/dgab795.

Angelo Sabag 1 2, Loren Barr 2, Mike Armour 1 3, Alex Armstrong 4, Callum J Baker 5, Stephen M Twigg 5 6, Dennis Chang 1, Daniel A Hackett 4, Shelley E Keating 7, Jacob George 8, Nathan A Johnson 4 9
 
17.Genome-Wide Association Study of NAFLD Using Electronic Health Records
 

Hepatol Commun. 2022 Feb;6(2):297-308. doi: 10.1002/hep4.1805.Epub 2021 Sep 17.

Cameron J Fairfield 1, Thomas M Drake 1, Riinu Pius 1, Andrew D Bretherick 2, Archie Campbell 1 3 4, David W Clark 5, Jonathan A Fallowfield 6, Caroline Hayward 2, Neil C Henderson 6, Peter K Joshi 5, Nicholas L Mills 7, David J Porteous 3, Prakash Ramachandran 6, Robert K Semple 7, Catherine A Shaw 1, Cathie L M Sudlow 1, Paul R H J Timmers 2 5, James F Wilson 2 5, Stephen J Wigmore 8, Ewen M Harrison # 1 8, Athina Spiliopoulou # 5
 
18.Is there an 'ideal' diet for patients with NAFLD?
 

Eur J Clin Invest. 2022 Mar;52(3):e13659. doi: 10.1111/eci.13659. Epub 2021 Aug 2

Nicola Pugliese 1 2, Maria Corina Plaz Torres 2 3, Salvatore Petta 4, Luca Valenti 5 6, Edoardo G Giannini 3, Alessio Aghemo 1 2
 
19.Nonalcoholic Fatty Liver Disease in Children
 

Gastroenterol Hepatol (N Y). 2021 Dec;17(12):579-587.

Katherine F Sweeny 1, Christine K Lee 1 2
 
20.A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach
 

Aliment Pharmacol Ther. 2022 Jan;55(2):234-243. doi: 10.1111/apt.16720. Epub 2021 Dec 5.

Jeffrey V Lazarus 1 2, Henry E Mark 2, Massimo Colombo 2 3, Sandro Demaio 4, John F Dillon 5, Jacob George 6, Hannes Hagström 7, Samantha Hocking 6, Nancy Lee 8, Mark J Nieuwenhuijsen 1, Mary E Rinella 9, Manuel Romero-Gomez 10, Joan B Soriano 11, Jörn M Schattenberg 12, Frank Tacke 13, Emmanuel A Tsochatzis 14, Luca Valenti 3, Shira Zelber-Sagi 15 16, M Ashworth Dirac 17, Terry T-K Huang 18
 
21.Liver Disease: Nonalcoholic Fatty Liver Disease
 

FP Essent. 2021 Dec;511:29-35.

Julia Cooper 1, Katrina Baumgartner 2, Andrew Smith 2, Joshua St Louis 2
 
22.Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease
 

Children (Basel). 2022 Mar 8;9(3):374. doi: 10.3390/children9030374.

Eduardo Castillo-Leon 1 2, Heather L Morris 3, Cheryl Schoen 3, Jacob Bilhartz 4, Patrick McKiernan 5, Tamir Miloh 6, Sirish Palle 7, Mohammad Nasser Kabbany 8, Breda Munoz 3, Andrea R Mospan 3, Bryan Rudolph 9, Stavra A Xanthakos 10, Miriam B Vos 11, Target-Nash Investigators
 
23.Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis
 

Aliment Pharmacol Ther. 2021 Dec;54(11-12):1405-1415. doi: 10.1111/apt.16664.Epub 2021 Oct 20.

Rifaat Safadi 1, Marius Braun 2, Adi Francis 3, Yael Milgrom 1, Muhammad Massarwa 1, David Hakimian 1, Wadi Hazou 1, Assaf Issachar 2, Zivit Harpaz 4, Motti Farbstein 4, Inbal Itzhak 4, Naama Lev-Cohain 5, Avital Bareket-Samish 6, Michael H Silverman 4, Pnina Fishman 4
 
24.Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis
 

Hepatology. 2022 May;75(5):1235-1246. doi: 10.1002/hep.32204. Epub 2022 Feb 7.

Arun J Sanyal 1, Quentin M Anstee 2, Michael Trauner 3, Eric J Lawitz 4, Manal F Abdelmalek 5 6, Dora Ding 7, Ling Han 7, Catherine Jia 7, Ryan S Huss 7, Chuhan Chung 7, Vincent Wai-Sun Wong 8, Takeshi Okanoue 9, Manuel Romero-Gomez 10, Andrew J Muir 5 6, Nezam H Afdhal 11, Jaime Bosch 12 13, Zachary Goodman 14, Stephen A Harrison 15, Zobair M Younossi 14, Robert P Myers 7
 
25.Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: implications for future trial design
 

Diabetes Metab. 2022 Mar;48(2):101281. doi: 10.1016/j.diabet.2021.101281.Epub 2021 Sep 17.

Pierpaolo Pellicori 1, Muthiah Vaduganathan 2, João Pedro Ferreira 3, Faiez Zannad 4, Arun J Sanyal 5
 
26.Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease
 

Am J Gastroenterol. 2021 Dec 1;116(12):2399-2409.doi: 10.14309/ajg.0000000000001375.

Stephen A Harrison 1, Seth J Baum 2, Nadege T Gunn 3, Ziad H Younes 4, Anita Kohli 5, Rashmee Patil 6, Margaret J Koziel 7, Harinder Chera 7, Jeff Zhao 7, Manu V Chakravarthy 7
 
27.Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin
 

J Pediatr. 2021 Dec;239:161-167.e5.doi: 10.1016/j.jpeds.2021.08.012. Epub 2021 Aug 13.

Samer Gawrieh 1, Kathryn E Harlow 2, Francis Pike 3, Katherine P Yates 4, Laura A Wilson 4, Oscar W Cummings 5, William M Rosenberg 6, Naga Chalasani 7, Jean P Molleston 2
 
28.JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk
 

J Clin Lipidol. Mar-Apr 2022;16(2):115-127. doi: 10.1016/j.jacl.2022.03.007.

Kathleen L Wyne 1, Sheldon E Litwin 2, Kenneth Cusi 3, John R Guyton 4
 
29.Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study
 

Clin Gastroenterol Hepatol. 2022 Feb;20(2):458-460.e4. doi: 10.1016/j.cgh.2021.03.031.Epub 2021 Mar 26.

Mary J Thomson 1, Marina Serper 2, Vandana Khungar 2, L Michael Weiss 3, Huy Trinh 4, Roberto Firpi-Morell 5, Michael Roden 6, Rohit Loomba 7, A Sidney Barritt 4th 8, Derek Gazis 9, Andrea R Mospan 9, Michael W Fried 9, K Rajender Reddy 2, Anna S Lok 10
 
30.The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
 

J Hepatol. 2022 Apr;76(4):771-780. doi: 10.1016/j.jhep.2021.10.025. Epub 2021 Dec 9.

Jeffrey V Lazarus 1, Henry E Mark 2, Marcela Villota-Rivas 3, Adam Palayew 4, Patrizia Carrieri 5, Massimo Colombo 6, Mattias Ekstedt 7, Gamal Esmat 8, Jacob George 9, Giulio Marchesini 10, Katja Novak 11, Ponsiano Ocama 12, Vlad Ratziu 13, Homie Razavi 14, Manuel Romero-Gómez 15, Marcelo Silva 16, C Wendy Spearman 17, Frank Tacke 18, Emmanuel A Tsochatzis 19, Yusuf Yilmaz 20, Zobair M Younossi 21, Vincent W-S Wong 22, Shira Zelber-Sagi 23,  Helena Cortez-Pinto 24, Quentin M Anstee 25, NAFLD policy review collaborators

Collaborators

  • NAFLD policy review collaborators: 

Samir Rouabhia  26 , Hasmik Ghazinyan   27,  Natacha Jreige Iskandar  28, Michael Trauner   29,  Gulnara Aghayeva  30, Flloyd Carter   31, Kannan Sridharan   32, Mamun Al Mahtab   33, Sven Francque   34, Nicolas Kodjoh   35,  Ruben Muñoz Camacho  36, Motswedi Anderson   37,  Claudia Pinto Marques Souza de Oliveira  38,  Lyudmila Mateva  39, Abdel Karim Serme   40,  Antonieta A Soares Martins  41,  Mark G Swain  42,  Narcisse Patrice Komas  43, Ming-Hua Zheng   44, Patricio Lopez Jaramillo   45, Omar Alfaro Murillo   46,  Ivana Mikolasevic  47, Emmelia Vounou   48, Radan Bruha   49, Charles Mbendi Nlombi   50, Maja Thiele   51, Marlene Perez   52, Juan José Suárez M  53,  Imam Waked  54, Riina Salupere   55, Hailemichael Desalegn   56, Hannele Yki-Järvinen 57, Tengiz Tsertsvadze 58, Lali Sharvadze 58, Maia Butsashvili 58, Yaw Asante Awuku 59, Georgios Papatheodoridis 60, Bela Hunyady 61, Einar Stefan Bjornsson 62, Ajay Duseja 63, Cosmas Rinaldi A Lesmana 64, Reza Malekzadeh 65, Suzanne Norris 66, Kazuhiko Koike 67, Alexander V Nersesov 68, Missiani Ochwoto 69, Mohammad Jamal 70, Tobokalova Saparbu 71, Ieva Tolmane 72, Raymond Sayegh 73, Dhastagir Sultan Sheriff 74, Jonas Valantinas 75, Joseph Weber 76, Isaac Thom Shawa 77, Soek-Siam Tan 78, Sophia E Martínez Vázquez 79, Oidov Baatarkhuu 80, Undram Lkhagvaa 80, Tsolmon Jadamba 80, Tahiri Mohammed 81, K C Sudhamshu 82, Kirsten Coppell 83 , Charles Onyekwere 84,&nbs
 
31.Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study
 

BMJ Open. 2022 Mar 30;12(3):e056159. doi: 10.1136/bmjopen-2021-056159.

Neeta B Amin 1, Amanda Darekar 2, Quentin M Anstee 3, Vincent Wai-Sun Wong 4, Frank Tacke 5, Manoli Vourvahis 6, Douglas S Lee 7, Michael Charlton 8, Naim Alkhouri 9, Atsushi Nakajima 10, Carla Yunis 6
 
32.Perspective: Is it Time to Expand Research on 'Nuts' to Include 'Seeds'? Justifications and Key Considerations
 

Adv Nutr. 2022 Mar 25;nmac028. doi: 10.1093/advances/nmac028. Online ahead of print.

Elena S George 1, Robin M Daly 1, Siew Ling Tey 2, Rachel Brown 2, Tommy Hon Ting Wong 3, Sze-Yen Tan 1
 
33.Perspective: Is it Time to Expand Research on
 

Adv Nutr. 2022 Mar 25;nmac028. doi: 10.1093/advances/nmac028. Online ahead of print.

Elena S George 1, Robin M Daly 1, Siew Ling Tey 2, Rachel Brown 2, Tommy Hon Ting Wong 3, Sze-Yen Tan 1
 
34.Metabolic dysfunction-related liver disease as a risk factor for cancer
 

BMJ Open Gastroenterol. 2022 Mar;9(1):e000817. doi: 10.1136/bmjgast-2021-000817.

Alasdair Taylor 1, Moneeza K Siddiqui 1, Philip Ambery 2, Javier Armisen 3, Benjamin G Challis 4, Carolina Haefliger 5, Ewan R Pearson 1, Alex S F Doney 1, John F Dillon 6, Colin N A Palmer 7
 
35.Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score
 

Hepatology. 2022 Mar 25. doi: 10.1002/hep.32475. Online ahead of print.

Rish K Pai 1, Vipul Jairath 2 3 4, Malcolm Hogan 3, Guangyong Zou 3 4 5, Oyedele A Adeyi 6, Quentin M Anstee 7 8, Bashar A Aqel 9, Cynthia Behling 10 11, Elizabeth J Carey 9, Andrew D Clouston 12, Kathleen Corey 13 14, Brian G Feagan 2 3 4, David E Kleiner 15, Christopher Ma 3 16 17, Stefanie C McFarlane 3, Mazen Noureddin 18, Vlad Ratziu 19, Mark A Valasek 20, Zobair M Younossi 21 22, Stephen A Harrison 23 24, Rohit Loomba 25
 
36.Impact of a Mediterranean Diet on Hepatic and Metabolic outcomes in Non-Alcoholic Fatty Liver Disease: The MEDINA Randomised Controlled Trial
 

Liver Int. 2022 Mar 31. doi: 10.1111/liv.15264. Online ahead of print.

Elena S George 1 2, Anjana Reddy 2, Amanda J Nicoll 3, Marno Ryan 4, Catherine Itsiopoulos 2 5, Gavin Abbott 1, Nathan A Johnson 6, Siddharth Sood 7, Stuart K Roberts 8 9, Audrey C Tierney 2 10
 
37.Bariatric Surgery in NAFLD
 

Dig Dis Sci. 2022 Feb;67(2):408-422. doi: 10.1007/s10620-021-07317-3.Epub 2022 Jan 4.

Mahak Chauhan 1, Kuldeep Singh 1, Paul J Thuluvath 2 3
 
38.Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials
 

Expert Opin Investig Drugs. 2022 Feb;31(2):163-172. doi:10.1080/13543784.2022.2032640.Epub 2022 Feb 10.

Pankaj Aggarwal 1, Mazen Noureddin 2, Stephen Harrison 3, Sophie Jeannin 4, Naim Alkhouri 5
 
39.Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week
 

J Am Coll Cardiol. 2022 Jan 18;79(2):180-191. doi: 10.1016/j.jacc.2021.11.007.

Alessandro Mantovani 1, Christopher D Byrne 2, Giovanni Benfari 3, Stefano Bonapace 4, Tracey G Simon 5, Giovanni Targher 6
 
40.Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE)
 

PLoS One. 2021 Nov 30;16(11):e0260320. doi: 10.1371/journal.pone.0260320.eCollection 2021.

Wayne Eskridge 1, John M Vierling 2, Wayne Gosbee 3, Gabriella A Wan 1, May-Linh Hyunh 1, Henry E Chang 1
 
41.Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care
 

J Clin Med. 2021 Dec 9;10(24):5755. doi: 10.3390/jcm10245755.

Laurence J Dobbie 1, Mohamed Kassab 2, Andrew S Davison 3 4, Pete Grace 4, Daniel J Cuthbertson 1, Theresa J Hydes 1 2
 
42.Selective Isolation of Liver-Derived Extracellular Vesicles Redefines Performance of miRNA Biomarkers for Non-Alcoholic Fatty Liver Disease
 

Biomedicines. 2022 Jan 17;10(1):195. doi: 10.3390/biomedicines10010195.

Lauren A Newman 1, Zivile Useckaite 1, Jillian Johnson 2, Michael J Sorich 1, Ashley M Hopkins 1, Andrew Rowland 1
 
43.Point Shear Wave Elastography by ElastPQ for Fibrosis Screening in Patients with NAFLD: A Prospective, Multicenter Comparison to Vibration-Controlled Elastography
 

Ultraschall Med. 2022 Feb 28. doi: 10.1055/a-1724-7289. Online ahead of print.

David Jm Bauer 1 2, Vladimir Matic 3, Ruxandra Mare 4, Laura Maiocchi 5, David Chromy 1 2, Theresa Müllner-Bucsics 1 2, Mattias Mandorfer 1 2, Sandra Mustapic 3, Ioan Sporea 6, Giovanna Ferraioli 5, Ivica Grgurevic 3, Thomas Reiberger 1 2 7
 
44.Life Expectancy after Liver Transplantation for NASH
 

Prog Transplant. 2022 Mar 30;15269248221087441. doi: 10.1177/15269248221087441.Online ahead of print.

Robert M Shavelle 1, Rachel C Saur 1, Ji Hun Kwak 1, Jordan C Brooks 1, Bilal Hameed 2
 
45.Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial
 

Lancet Gastroenterol Hepatol. 2022 Mar 21;S2468-1253(22)00017-6.doi: 10.1016/S2468-1253(22)00017-6. Online ahead of print.

Stephen A Harrison 1, Manal F Abdelmalek 2, Guy Neff 3, Nadege Gunn 4, Cynthia D Guy 5, Naim Alkhouri 6, Mustafa R Bashir 7, Bradley Freilich 8, Anita Kohli 9, Arun Khazanchi 10, Muhammad Y Sheikh 11, Mark Leibowitz 12, Mary E Rinella 13, Mohammad S Siddiqui 14, Mark Kipnes 15, Sam E Moussa 16, Ziad H Younes 17, Meena Bansal 18, Seth J Baum 19, Brian Borg 20, Peter J Ruane 21, Paul J Thuluvath 22, Mildred Gottwald 23, Mujib Khan 23, Charles Chen 23, Liza Melchor-Khan 23, William Chang 23, Alex M DePaoli 23, Lei Ling 24, Hsiao D Lieu 23
 
46.Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
 

Metabolites. 2022 Mar 11;12(3):238. doi: 10.3390/metabo12030238.

Ryan D Welch 1, Cyrielle Billon 2, McKenna Losby 3, Gonzalo Bedia-Diaz 2, Yuanying Fang 2, Amer Avdagic 2, Bahaa Elgendy 2 4, Thomas P Burris 5, Kristine Griffett 6
 
47.Focal fatty sparing as an indicator of higher-grade fatty liver assessed by attenuation imaging: a prospective clinical study in NAFLD population
 

Z Gastroenterol. 2021 Dec 14. doi: 10.1055/a-1695-3637. Online ahead of print.

Elisabeth Miller 1, Julian Schmidberger 1, Wolfgang Kratzer 1
 
48.Sleeve gastrectomy prior to liver transplantation is superior to medical weight loss in reducing posttransplant metabolic complications
 

Am J Transplant. 2021 Oct;21(10):3324-3332. doi: 10.1111/ajt.16583. Epub 2021 May 3.

Suzanne R Sharpton 1, Norah A Terrault 2, Mehdi M Tavakol 3, Andrew M Posselt 3
 
49.The fecal mycobiome in non-alcoholic fatty liver disease
 

J Hepatol. 2022 Apr;76(4):788-799. doi: 10.1016/j.jhep.2021.11.029. Epub 2021 Dec 10.

Münevver Demir 1, Sonja Lang 2, Phillipp Hartmann 3, Yi Duan 4, Anna Martin 5, Yukiko Miyamoto 4, Marina Bondareva 6, Xinlian Zhang 7, Yanhan Wang 4, Philipp Kasper 5, Corinna Bang 8, Christoph Roderburg 9, Frank Tacke 1, Hans-Michael Steffen 5, Tobias Goeser 5, Andrey Kruglov 6, Lars Eckmann 4, Peter Stärkel 10, Derrick E Fouts 11, Bernd Schnabl 12
 
50.Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?
 

Gut. 2022 Feb;71(2):382-390. doi: 10.1136/gutjnl-2020-322564. Epub 2021 Feb 4.

Ramy Younes 1 2 3, Olivier Govaere 1, Salvatore Petta 4, Luca Miele 5 6, Dina Tiniakos 1 7, Alastair Burt 1, Ezio David 3, Fabio Maria Vecchio 5 8, Marco Maggioni 9, Daniela Cabibi 10, Duncan McLeod 11, Maria Jesus Pareja 12, Anna Ludovica Fracanzani 13, Rocio Aller 14, Chiara Rosso 3, Javier Ampuero 15, Rocío Gallego-Durán 15, Angelo Armandi 3, Gian Paolo Caviglia 3, Marco Y W Zaki 1 16, Antonio Liguori 5, Paolo Francione 13, Grazia Pennisi 4, Antonio Grieco 5 6, Giovanni Birolo 3, Piero Fariselli 3, Mohammed Eslam 17, Luca Valenti 18, Jacob George 17, Manuel Romero-Gómez 15, Quentin Mark Anstee 19 20, Elisabetta Bugianesi 21
 
51.Dietary sugar restriction reduces hepatic de novo lipogenesis in adolescent boys with fatty liver disease
 

J Clin Invest. 2021 Dec 15;131(24):e150996. doi: 10.1172/JCI150996.

Catherine C Cohen 1 2, Kelvin W Li 3, Adina L Alazraki 4 5, Carine Beysen 6, Carissa A Carrier 7, Rebecca L Cleeton 1, Mohamad Dandan 3, Janet Figueroa 1, Jack Knight-Scott 5, Cynthia J Knott 8, Kimberly P Newton 7 9, Edna M Nyangau 3, Claude B Sirlin 10, Patricia A Ugalde-Nicalo 7 9, Jean A Welsh 1 11, Marc K Hellerstein 3, Jeffrey B Schwimmer 7 9, Miriam B Vos 1 11
 
52.Deep proteomic profiling unveils arylsulfatase A as a non-alcoholic steatohepatitis inducible hepatokine and regulator of glycemic control
 

Nat Commun. 2022 Mar 10;13(1):1259. doi: 10.1038/s41467-022-28889-2.

Magdalene K Montgomery 1, Jacqueline Bayliss 2, Shuai Nie 3, William De Nardo 2, Stacey N Keenan 2, Paula M Miotto 2, Hamzeh Karimkhanloo 2 4, Cheng Huang 5, Ralf B Schittenhelm 5, Anthony S Don 6, Andrew Ryan 7, Nicholas A Williamson 3, Geraldine J Ooi 8, Wendy A Brown 8, Paul R Burton 8, Benjamin L Parker 2, Matthew J Watt 9
 
53.Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence?
 

World J Hepatol. 2021 Dec 27;13(12):1816-1827.

doi: 10.4254/wjh.v13.i12.1816.

Huw Purssell 1, Peter J Whorwell 2, Varinder S Athwal 1, Dipesh H Vasant 2
 
54.Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants
 

J Hepatol. 2022 Jan 24;S0168-8278(22)00023-X. doi: 10.1016/j.jhep.2022.01.010.Online ahead of print.

Fanny Petermann-Rocha 1, Stuart R Gray 2, Ewan Forrest 3, Paul Welsh 2, Naveed Sattar 2, Carlos Celis-Morales 4, Frederick K Ho 5, Jill P Pell 6
 
55.Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD
 

J Hepatol. 2022 Jan 25;S0168-8278(22)00024-1. doi: 10.1016/j.jhep.2022.01.011.Online ahead of print.

Elizabeth M Brunt 1, Andrew D Clouston 2, Zachary Goodman 3, Cynthia Guy 4, David E Kleiner 5, Carolin Lackner 6, Dina G Tiniakos 7, Aileen Wee 8, Matthew Yeh 9, Wei Qiang Leow 10, Elaine Chng 11, Yayun Ren 11, George Goh Boon Bee 12, Elizabeth E Powell 13, Mary Rinella 14, Arun J Sanyal 15, Brent Neuschwander-Tetri 16, Zobair Younossi 17, Michael Charlton 18, Vlad Ratziu 19, Stephen A Harrison 20, Dean Tai 21, Quentin M Anstee 22
 
56.A problem of proportions: estimates of metabolic associated fatty liver disease and liver fibrosis in Australian adults in the nationwide 2012 AusDiab Study
 

Sci Rep. 2022 Feb 4;12(1):1956. doi: 10.1038/s41598-022-05168-0.

Ann M Farrell 1 2, Dianna J Magliano 3, Jonathan E Shaw 3, Alexander J Thompson 4 5, Catherine Croagh 4 5, Marno C Ryan 4 5, Jessica Howell 4 5 6 7
 
57.Nonalcoholic Fatty Liver Disease (NAFLD) Name Change: Requiem or Reveille?
 

J Clin Transl Hepatol. 2021 Dec 28;9(6):931-938. doi: 10.14218/JCTH.2021.00174.Epub 2021 Aug 24.

Shivaram P Singh 1, Prajna Anirvan 1, Reshu Khandelwal 1, Sanjaya K Satapathy 2
 
58.Ethnic and gender differences in hepatic lipid content and related cardiometabolic parameters in lean individuals
 

JCI Insight. 2022 Feb 15;e157906. doi: 10.1172/jci.insight.157906. Online ahead of print.

Kitt Falk Petersen 1, Sylvie Dufour 1, Fangyong Li 2, Douglas L Rothman 3, Gerald I Shulman 1
 
59.Liver biopsy for assessment of chronic liver diseases: a synopsis
 

Clin Exp Med. 2022 Feb 22. doi: 10.1007/s10238-022-00799-z.Online ahead of print.

Aqib B Chowdhury 1, Kosha J Mehta 2
 
60.NAFLD and the Gut-Liver Axis: Exploring an Undernutrition Perspective
 

Gastroenterology. 2022 Mar 3;S0016-5085(22)00203-7.doi: 10.1053/j.gastro.2022.01.058. Online ahead of print.

Kylynda C Bauer 1, Paula T Littlejohn 2, Victoria Ayala 3, Anna Creus-Cuadros 4, B Brett Finlay 5
 
61.Interactions of physical activity, muscular fitness, adiposity, and genetic risk for NAFLD
 

Hepatol Commun. 2022 Mar 15. doi: 10.1002/hep4.1932. Online ahead of print.

Theresia M Schnurr 1 2, Sophia Figueroa Katz 1 3, Johanne M Justesen 1 2, Jack W O'Sullivan 1, Peter Saliba-Gustafsson 1 4, Themistocles L Assimes 1 5, Ivan Carcamo-Orive 1 6, Aijaz Ahmed 7, Euan A Ashley 1 8 9, Torben Hansen 2, Joshua W Knowles 1 6 10
 
62.Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD)
 

Aliment Pharmacol Ther. 2022 Mar 17. doi: 10.1111/apt.16874. Online ahead of print.

Danielle Brandman 1, Marie Boyle 2 3, Stuart McPherson 2 3, Mark L Van Natta 4, Arun J Sanyal 5, Kris Kowdley 6, Brent Neuschwander-Tetri 7, Naga Chalasani 8, Manal F Abdelmalek 9, Norah A Terrault 10, Art McCullough 11, Ricki Bettencourt 12, Cyrielle Caussy 12, David E Kleiner 13, Cynthia Behling 14, James Tonascia 4, Quentin M Anstee 2, Rohit Loomba 12, Members of the Nonalcoholic Steatohepatitis Clinical Research Network
 
63.Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update
 

Biomedicines. 2022 Jan 17;10(1):194. doi: 10.3390/biomedicines10010194.

Laura Giuseppina Di Pasqua 1, Marta Cagna 1, Clarissa Berardo 1, Mariapia Vairetti 1, Andrea Ferrigno 1
 
64.Analysis of Liver Responses to Non-alcoholic Steatohepatitis by mRNA-Sequencing
 

Methods Mol Biol. 2022;2455:163-179. doi: 10.1007/978-1-0716-2128-8_14.

Christopher D Green 1, Mikhail G Dozmorov 2, Sarah Spiegel 3
 
65.T cells: Friends and foes in NASH pathogenesis and hepatocarcinogenesis
 

Hepatology. 2022 Jan 12. doi: 10.1002/hep.32336. Online ahead of print.

Pierluigi Ramadori 1, Shing Kam 1, Mathias Heikenwalder 1
 
66.Hepatic fibrosis 2022: Unmet needs and a blueprint for the future
 

Hepatology. 2022 Feb;75(2):473-488. doi: 10.1002/hep.32285. Epub 2022 Jan 11.

Scott L Friedman 1, Massimo Pinzani 2
 
67.The Origins of NAFLD: The Potential Implication of Intrauterine Life and Early Postnatal Period
 

Cells. 2022 Feb 5;11(3):562. doi: 10.3390/cells11030562.

Francesco Valentini 1, Giulia Rocchi 2, Umberto Vespasiani-Gentilucci 3, Michele Pier Luca Guarino 4, Annamaria Altomare 4, Simone Carotti 5
 
68.The NAFLD-MAFLD debate: Is there a Consensus-on-Consensus methodology?
 

Yasser Fouad 1, Jean-François Dufour 2 3, Ming-Hua Zheng 4 5 6, Steven Bollipo 7, Hailemichael Desalegn 8, Henning Grønbaek 9, Robert G Gish 10
 
69.A global view of the interplay between non-alcoholic fatty liver disease and diabetes
 

Lancet Diabetes Endocrinol. 2022 Feb 17;S2213-8587(22)00003-1.doi: 10.1016/S2213-8587(22)00003-1. Online ahead of print.

Norbert Stefan 1, Kenneth Cusi 2
 
70.Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes
 

Liver Int. 2022 Feb 26.doi: 10.1111/liv.15209. Online ahead of print.

Patrizia Carrieri 1, Abbas Mourad 1, Fabienne Marcellin 1, Aldo Trylesinski 2, José Luis Calleja 3, Camelia Protopopescu 1, Jeffrey V Lazarus 4 5
 
71.Non-alcoholic Steatohepatitis: From Pathophysiology to Clinical Practice
 

touchREV Endocrinol. 2021 Nov;17(2):112-120. doi: 10.17925/EE.2021.17.2.112.Epub 2021 Sep 14.

Sherwyn Schwartz 1, Jean Lucas 2, Mark H DeLegge 3
 
72.Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: Data from the United States Scientific Registry of Transplant Recipients
 

Hepatol Commun. 2022 Feb 28. doi: 10.1002/hep4.1915. Online ahead of print.

Maria Stepanova 1 2, Khaled Kabbara 1 3, Denise Mohess 4, Manisha Verma 1 4, Alva Roche-Green 4, Saleh AlQahtani 2 5, Janus Ong 2 6, Patrizia Burra 2 7, Zobair M Younossi 1 2 3 8
 
73.Factors impacting survival in those transplanted for NASH cirrhosis: Data from the NailNASH Consortium
 

Clin Gastroenterol Hepatol. 2022 Feb 18;S1542-3565(22)00184-7.doi: 10.1016/j.cgh.2022.02.028. Online ahead of print.

Mary E Rinella, Sanjaya K Satapathy, Danielle Brandman, Coleman Smith, Sal Elwir, Jonathan Xia, Meg Gibson, Carlos Figueredo, Mounika Angirekula, Jason M Vanatta, Raiya Sarwar, Yu Jiang, Dyanna Gregory, Tandy Agostini, JimIn Ko, Pradeep Podila, Grace Gallo, Kymberly D Watt, Mohammad S Siddiqui
 
74.Trends in the Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in the United States, 2011-2018
 

Clin Gastroenterol Hepatol. 2022 Mar;20(3):e610-e613. doi: 10.1016/j.cgh.2021.01.030.Epub 2021 Jan 22.

Robert J Wong 1, Ramsey Cheung 2
 
75.Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, and Regional Amyloid-ß and Tau Pathology in Middle-Aged Adults: The Framingham Study
 

J Alzheimers Dis. 2022 Feb 21. doi: 10.3233/JAD-215409. Online ahead of print.

Galit Weinstein 1, Adrienne O'Donnell 2 3, Kendra Davis-Plourde 2 3, Shira Zelber-Sagi 1 4, Saptaparni Ghosh 3 5, Charles S DeCarli 6, Emma G Thibault 7, Reisa A Sperling 7 8, Keith A Johnson 7 8, Alexa S Beiser 2 3 5, Sudha Seshadri 3 5 9
 
76.Comparison of the Lipidomic Signature of Fatty Liver in Children and Adults: A Cross-Sectional Study
 

J Pediatr Gastroenterol Nutr. 2022 Feb 21. doi: 10.1097/MPG.0000000000003418.Online ahead of print.

Jake P Mann 1, Benjamin Jenkins, Samuel Furse, Stuart G Snowden, Anna Alisi, Laura G Draijer, Kylie Karnebeek, Deirdre A Kelly, Bart G Koot, Antonella Mosca, Camilla Salvestrini, Indra van Mourik, Anita Vreugdenhil, Matthias Zilbauer, Albert Koulman, EU-PNAFLD investigators^
 
77.Clinical Intervention to Reduce Dietary Sugar does not Impact Liver Fat in Latino Youth, Regardless of PNPLA3 Genotype: A Randomized Controlled Trial
 

J Nutr. 2022 Feb 26;nxac046. doi: 10.1093/jn/nxac046. Online ahead of print.

Kelsey A Schmidt 1, Roshonda B Jones 1, Claudia Rios 1, Yesica Corona 1, Paige K Berger 1, Jasmine F Plows 1, Tanya L Alderete 2, Jennifer Fogel 1, Hailey Hampson 1 3, Jaana A Hartiala 4, Zhiheng Cai 5, Hooman Allayee 5 4, Krishna S Nayak 6 7, Frank R Sinatra 3, Gregory Harlan 3, Trevor A Pickering 4, Sarah-Jeanne Salvy 8, Wendy Mack 4, Rohit Kohli 9, Michael I Goran 1
 
78.Dietary Patterns and Prevalent NAFLD at Year 25 from the Coronary Artery Risk Development in Young Adults (CARDIA) Study
 

Nutrients. 2022 Feb 18;14(4):854. doi: 10.3390/nu14040854.

Meagan E Gray 1, Sejong Bae 2, Rekha Ramachandran 2, Nicholas Baldwin 3, Lisa B VanWagner 4 5, David R Jacobs Jr 6, James G Terry 7, James M Shikany 2
 
79.Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery
 

Hepatology. 2022 Jan 25. doi: 10.1002/hep.32358. Online ahead of print.

Raluca Pais 1 2 3 4, Judith Aron-Wisnewsky 1 2 5, Pierre Bedossa 6, Maharajah Ponnaiah 3, Jean-Michel Oppert 1 2, Jean-Michel Siksik 1, Laurent Genser 1 2 5, Frederic Charlotte 1 2, Dominique Thabut 1 2 4, Karine Clement 1 2 5, Vlad Ratziu 1 2 3 6
 
80.NASH: regulatory considerations for clinical drug development and U.S. FDA approval
 

Acta Pharmacol Sin. 2022 Jan 21. doi: 10.1038/s41401-021-00832-z. Online ahead of print.

Brian E Harvey 1
 
81.Agreement Between the Prevalence of Nonalcoholic Fatty Liver Disease Determined by Transient Elastography and Fatty Liver Indices
 

Clin Gastroenterol Hepatol. 2022 Jan;20(1):227-229.e2. doi: 10.1016/j.cgh.2020.11.028.Epub 2020 Nov 20.

Gieira S Jones 1, Christian S Alvarez 1, Barry I Graubard 1, Katherine A McGlynn 2
 
82.Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis
 

Gut. 2022 Jan;71(1):156-162. doi: 10.1136/gutjnl-2020-323082.Epub 2020 Dec 10.

Alessandro Mantovani 1, Graziana Petracca 1, Giorgia Beatrice 1, Alessandro Csermely 1, Amedeo Lonardo 2, Jörn M Schattenberg 3, Herbert Tilg 4, Christopher D Byrne 5, Giovanni Targher 6
 
83.NAFLD Cirrhosis Is Rising Among Childbearing Women and Is the Most Common Cause of Cirrhosis in Pregnancy
 

Clin Gastroenterol Hepatol. 2022 Feb;20(2):e315-e318. doi: 10.1016/j.cgh.2021.01.022.Epub 2021 Jan 16.

Monika Sarkar 1, Maya Djerboua 2, Jennifer A Flemming 3
 
84.Sleep disruption in nonalcoholic fatty liver disease: What is the role of lifestyle and diet?
 

Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e308-e312.doi: 10.1097/MEG.0000000000002049.

Siddique T Akram 1, Matthew W Ewy 2, Adnan Said 3 4
 
85.Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus
 

Clin Gastroenterol Hepatol. 2022 Feb;20(2):256-268.doi: 10.1016/j.cgh.2020.10.018. Epub 2020 Oct 16.

Jordan E Lake 1, Turner Overton 2, Susanna Naggie 3, Mark Sulkowski 4, Rohit Loomba 5, David E Kleiner 6, Jennifer C Price 7, Kara W Chew 8, Raymond T Chung 9, Kathleen E Corey 9
 
86.Is it time for chronopharmacology in NASH?
 

J Hepatol. 2022 Jan 20;S0168-8278(22)00010-1. doi: 10.1016/j.jhep.2021.12.039.Online ahead of print.

Thomas Marjot 1, David W Ray 2, Jeremy W Tomlinson 3
 
87.Fatty Liver Through the Ages: Nonalcoholic Steatohepatitis
 

Endocr Pract. 2022 Feb;28(2):204-213. doi: 10.1016/j.eprac.2021.12.010.Epub 2021 Dec 22.

Zobair M Younossi 1, Linda Henry 2
 
88.Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat
 

Clin Gastroenterol Hepatol. 2022 Jan 6;S1542-3565(22)00002-7. doi: 10.1016/j.cgh.2021.12.044.Online ahead of print.

Eric J Lawitz 1, Bal Raj Bhandari 2, Peter J Ruane 3, Anita Kohli 4, Eliza Harting 5, Dora Ding 5, Jen-Chieh Chuang 5, Ryan S Huss 5, Chuhan Chung 5, Robert P Myers 6, Rohit Loomba 7
 
89.Depressive symptoms in non-alcoholic fatty liver disease are identified by perturbed lipid and lipoprotein metabolism
 

PLoS One. 2022 Jan 6;17(1):e0261555. doi: 10.1371/journal.pone.0261555. eCollection 2022.

Daniel E Radford-Smith 1 2 3, Preya J Patel 4 5, Katharine M Irvine 6 7, Anthony Russell 8 9, Dan Siskind 10 11, Daniel C Anthony 1, Elizabeth E Powell 6 12, Fay Probert 2
 
90.Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD
 

Hepatology. 2022 Jan 9. doi: 10.1002/hep.32324. Online ahead of print.

Mary P Moore 1 2, Rory P Cunningham 1 2, Grace M Meers 1 2, Sarah A Johnson 1 3, Andrew A Wheeler 4, Rama R Ganga 4, Nicole M Spencer 4, James B Pitt 4, Alberto Diaz-Arias 5, Ahmed I A Swi 3, Ghassan M Hammoud 3, Jamal A Ibdah 1 2 3, Elizabeth J Parks 2 3, R Scott Rector 1 2 3
 
91.Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease
 

J Med Econ. 2022 Jan 17;1-29. doi: 10.1080/13696998.2022.2026702. Online ahead of print.

Vinod K Rustgi 1 2, Steve B Duff 3, Mohamed I Elsaid 1 4
 
92.Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD]
 

Metabol Open. 2022 Jan 5;13:100158. doi: 10.1016/j.metop.2021.100158. eCollection 2022 Mar.

David Bernstein 1, Alexander J Kovalic 1
 
93.Effects of Moderate Alcohol Consumption in Non-Alcoholic Fatty Liver Disease
 

J Clin Med. 2022 Feb 8;11(3):890. doi: 10.3390/jcm11030890.

Peter Lemmer 1 2, Paul Manka 1, Jan Best 1, Alisan Kahraman 3, Julia Kälsch 3, Ramiro Vilchez-Vargas 2, Alexander Link 2, Hsin Chiang 3, Guido Gerken 3, Ali Canbay 1, Lars P Bechmann 1, Svenja Sydor 1
 
94.Dietary patterns in non-alcoholic fatty liver disease (NAFLD): Stay on the straight and narrow path!
 

Clin Investig Arterioscler. 2022 Feb 4;S0214-9168(21)00155-8. doi: 10.1016/j.arteri.2021.10.001.Online ahead of print.

[Article in English, Spanish]

Niki Katsiki 1, Anca Pantea Stoian 2, Manfredi Rizzo 3
 
95.Clinical implications of hepatic structure and function evaluation based on vibration-controlled transient elastography and liver maximum function capacity test in patients with nonalcoholic fatty liver disease
 

Eur J Gastroenterol Hepatol. 2022 Jan 31. doi: 10.1097/MEG.0000000000002347.Online ahead of print.

Valentin Blank 1, David Petroff, Albrecht Boehlig, Aileen Heinze, Thomas Karlas, Thomas Berg, Johannes Wiegand
 
96.The paradigm shift from NAFLD to MAFLD: A global primary care viewpoint
 

Liver Int. 2022 Feb 7. doi: 10.1111/liv.15188. Online ahead of print.

Taghreed M Farahat 1, Mehmet Ungan 2, Josep Vilaseca 3, Jacqueline Ponzo 4, Pramendra Prasad Gupta 5, Andrew D Schreiner 6, Wadeia Al Sharief 7, Kelly Casler 8, Tafat Abdelkader 9, Ludovico Abenavoli 10, Fatima-Zohra Mchich Alami 11, Mattias Ekstedt 12, Muntadar Saad Jabir 13, Matthew J Armstrong 14, Mona Osman El Hage 15, Johannes Wiegand 16, Dina Attia 17, Veronique Verhoeven 18, Ashraf Abdul Qayoum Amir 19, Nagwa Nashat 1, Emmanuel A Tsochatzis 20, Yasser Fouad 21, Helena Cortez-Pinto 22
 
97.Exposure to maternal fuels during pregnancy and offspring hepatic fat in early childhood: The healthy start study
 

Pediatr Obes. 2022 Feb 5;e12902. doi: 10.1111/ijpo.12902. Online ahead of print.

Catherine C Cohen 1 2, Ellen C Francis 2, Wei Perng 2 3 4, Katherine A Sauder 1 2, Ann Scherzinger 5, Shikha S Sundaram 1, Kartik Shankar 1 2, Dana Dabelea 1 2 3
 
98.Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies
 

J Endocrinol Invest. 2022 Feb 11. doi: 10.1007/s40618-022-01755-0.Online ahead of print.

F Bellinato 1, P Gisondi 2, A Mantovani 3, G Girolomoni 2, G Targher 3
 
99.The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United States
 

Clin Gastroenterol Hepatol. 2021 Oct 16;S1542-3565(21)01131-9. doi: 10.1016/j.cgh.2021.10.018.

Zobair M Younossi 1, Michael Harring 2, Youssef Younossi 3, Janus P Ong 4, Saleh A Alqahtani 5, Maria Stepanova 6
 
100.NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH
 

Hepatology. 2021 Dec 10. doi: 10.1002/hep.32274. Online ahead of print.

Jonathan G Stine 1 2 3 4, Ian R Schreibman 1 3, Alison J Faust 1 3, Jessica Dahmus 1, Benjamin Stern 1, Christopher Soriano 1, Gloriany Rivas 1, Breianna Hummer 1, Scot R Kimball 5, Nate R Geyer 2, Vernon M Chinchilli 2, Rohit Loomba 6 7, Kathryn Schmitz 2 4 8 9, Christopher Sciamanna 2 4 10
 
101.The within-individual reproducibility of the disease severity index from the HepQuant SHUNT test of liver function and physiology
 

Transl Res. 2021 Jul;233:5-15. doi: 10.1016/j.trsl.2020.12.010. Epub 2021 Jan 2.

James R Burton Jr 1, Steven Helmke 2, Shannon Lauriski 3, John Kittelson 3, Gregory T Everson 2
 
102.Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study
 

Patient. 2021 Sep;14(5):533-543. doi: 10.1007/s40271-020-00485-w.Epub 2020 Dec 18.

Lynda C Doward 1, Maria-Magdalena Balp 2, James Twiss 3, Christina Slota 4, Donna Cryer 5, Clifford A Brass 6, Quentin M Anstee # 7 8, Arun J Sanyal # 9
 
103.Interaction Between Alcohol Consumption and PNPLA3 Variant in the Prevalence of Hepatic Steatosis in the US Population
 

Clin Gastroenterol Hepatol. 2021 Dec;19(12):2606-2614.e4. doi: 10.1016/j.cgh.2020.08.054.Epub 2020 Aug 31.

Mariana Lazo 1, Usama Bilal 2, Mack C Mitchell 3, James Potter 4, Ruben Hernaez 5, Jeanne M Clark 6
 
104.Clinical Utility of Change in Nonalcoholic Fatty Liver Disease Activity Score and Change in Fibrosis in NAFLD
 

Clin Gastroenterol Hepatol. 2021 Dec;19(12):2673-2674.e3. doi: 10.1016/j.cgh.2020.11.005.Epub 2020 Nov 3.

Nobuharu Tamaki 1, Nagambika Munaganuru 2, Jinho Jung 2, Aed Qas Yonan 2, Richele Bettencourt 2, Veeral Ajmera 2, Mark A Valasek 3, Cynthia Behling 4, Rohit Loomba 5
 
105.Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study
 

Eur J Gastroenterol Hepatol. 2021 Dec 1;33(12):1578-1581.doi: 10.1097/MEG.0000000000001902.

Mahmud Mahamid 1 2, Wiliam Nseir 3, Tawfik Khoury 4 5 6, Baker Mahamid 6, Adi Nubania 1 2, Kamal Sub-Laban 1 2, Joel Schifter 1 2, Amir Mari 5 6, Wisam Sbeit 4 5, Eran Goldin 1 2
 
106.Pediatric obesity-related non-alcoholic fatty liver disease: waist-to-height ratio best anthropometrical predictor
 

Pediatr Res. 2021 Jul;90(1):166-170. doi: 10.1038/s41390-020-01192-w. Epub 2020 Oct 10.

Giuseppina R Umano 1, Anna Grandone 2, Anna Di Sessa 2, Domenico Cozzolino 3, Marcella Pedullà 2, Pierluigi Marzuillo 2, Emanuele Miraglia Del Giudice 2
 
107.Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD
 

Mol Metab. 2021 Aug;50:101115. doi: 10.1016/j.molmet.2020.101115.Epub 2020 Nov 10.

Douglas G Mashek 1
 
108.Association of a 1 Antitrypsin Phenotype and Development of Advanced Liver Disease and Pulmonary Complications Before and After Liver Transplantation
 

Transplantation. 2021 Jul 1;105(7):1576-1584. doi: 10.1097/TP.0000000000003390.

Anan Abu Rmilah 1, Robert Fencl 2, Kymberly Watt 1, Michael Krowka 1, Russell Wiesner 1, David Murray 2, Scott Nyberg 1, Michael Leise 1
 
109.Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases
 

J Clin Gastroenterol. 2021 Nov-Dec 01;55(10):891-902. doi: 10.1097/MCG.0000000000001409.

Robert J Wong 1, Nandita Kachru 2, Diane J Martinez 3, Meghan Moynihan 3, A Burak Ozbay 2, Stuart C Gordon 4
 
110.Noninvasive biomarkers in predicting nonalcoholic steatohepatitis and assessing liver fibrosis: systematic review and meta-analysis
 

Panminerva Med. 2021 Dec;63(4):508-518. doi: 10.23736/S0031-0808.20.04171-3.Epub 2020 Nov 9.

Abdulrahman Ismaiel 1, Daniel-Corneliu Leucuta 2, Stefan-Lucian Popa 1, Sharmila Fagoonee 3, Rinaldo Pellicano 4, Ludovico Abenavoli 5, Dan L Dumitrascu 1
 
111.A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis
 

Clin Gastroenterol Hepatol. 2021 Dec;19(12):2670-2672. doi: 10.1016/j.cgh.2020.10.051.Epub 2020 Nov 2.

Mohammad Shadab Siddiqui 1, Michael O Idowu 2, Deven Parmar 3, Brian B Borg 4, Douglas Denham 5, Nicole M Loo 6, Donald Lazas 7, Ziad Younes 8, Arun J Sanyal 9
 
112.A personalized treatment program in persons with type 2 diabetes is associated with a reduction in liver steatosis
 

Eur J Gastroenterol Hepatol. 2021 Nov 1;33(11):1420-1426.doi: 10.1097/MEG.0000000000001882.

Karl Björkström 1, Per Stål 1 2, Magnus Holmer 1 2, Bonnie Bengtsson 1 2, Annika Staaf 1, Johan Hoffstedt 1, Hannes Hagström 1 2 3
 
113.Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD)
 

Visc Med. 2021 Aug;37(4):273-280. doi: 10.1159/000515445. Epub 2021 Apr 13.

Elke Roeb 1
 
114.Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease
 

Hepatol Commun. 2021 Sep 2. doi: 10.1002/hep4.1818. Online ahead of print.

Ashwini Arvind 1 2, Jacqueline B Henson 1 3, Stephanie A Osganian 2, Cheryl Nath 2, Lara M Steinhagen 2, Zoe N Memel 1 3, Arley Donovan 2, Oluwafemi Balogun 2, Raymond T Chung 1 2 4, Tracey G Simon 1 2 4, Kathleen E Corey 1 2 4
 
115.A Retrospective Study of Hospitalizations in the USA: Proportion of Hospitalizations With Non-Alcoholic Fatty Liver Disease in Non-Obese Population
 

Cureus. 2021 Sep 10;13(9):e17869. doi: 10.7759/cureus.17869. eCollection 2021 Sep.

Olubunmi Oladunjoye 1, Adeolu O Oladunjoye 2 3, Rashmi Dhital 1, DilliRam Poudel 4, Oreoluwa D Oladiran 5, Ibiyemi O Oke 1, Gabriel Areoye 1, Asad Jehangir 6, Oluwaseun Shogbesan 7
 
116.Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry
 

Clin Gastroenterol Hepatol. 2021 Nov 9;S1542-3565(21)01183-6.doi: 10.1016/j.cgh.2021.11.004.Online ahead of print.

Zobair M Younossi 1, Yusuf Yilmaz 2, Ming-Lung Yu 3, Vincent Wai-Sun Wong 4, Marlen Castellanos Fernandez 5, Vasily A Isakov 6, Ajay K Duseja 7, Nahum Mendez-Sanchez 8, Yuichiro Eguchi 9, Elisabetta Bugianesi 10, Patrizia Burra 11, Jacob George 12, Jian-Gao Fan 13, George V Papatheodoridis 14, Wah Kheong Chan 15, Khalid Alswat 16, Hamid S Saeed 17, Ashwani K Singal 18, Manuel Romero-Gomez 19, Stuart C Gordon 20, Stuart K Roberts 21, Mohamed El Kassas 22, Marcelo Kugelmas 23, Janus P Ong 24, Saleh Alqahtani 25, Mariam Ziayee 26, Brian Lam 27, Issah Younossi 28, Andrei Racila 27, Linda Henry 29, Maria Stepanova 29, Global NASH Council
 
117.Liver-related Mortality is Increased in Lean Subjects with Non- alcoholic Fatty Liver Disease Compared to Overweight and Obese Subjects
 

J Gastrointestin Liver Dis. 2021 Sep 21;30(3):366-373. doi: 10.15403/jgld-3622.

Alexandra Feldman 1, Bernhard Wernly 2, Georg Strebinger 3, Sebastian Karl Eder 4, Stephan Zandanell 5, David Niederseer 6, Michael Strasser 7, Heike Haufe 8, Karl Sotlar 9, Bernhard Paulweber 10, Christian Datz 11, Elmar Aigner 12
 
118.Noninvasive biomarkers in predicting nonalcoholic steatohepatitis and assessing liver fibrosis: systematic review and meta-analysis
 

Panminerva Med. 2021 Dec;63(4):508-518. doi: 10.23736/S0031-0808.20.04171-3.Epub 2020 Nov 9.

Abdulrahman Ismaiel 1, Daniel-Corneliu Leucuta 2, Stefan-Lucian Popa 1, Sharmila Fagoonee 3, Rinaldo Pellicano 4, Ludovico Abenavoli 5, Dan L Dumitrascu 1
 
119.A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis
 

Clin Gastroenterol Hepatol. 2021 Dec;19(12):2670-2672. doi: 10.1016/j.cgh.2020.10.051.Epub 2020 Nov 2.

Mohammad Shadab Siddiqui 1, Michael O Idowu 2, Deven Parmar 3, Brian B Borg 4, Douglas Denham 5, Nicole M Loo 6, Donald Lazas 7, Ziad Younes 8, Arun J Sanyal 9
 
120.Non-hepatic Cancers Independently Predict Liver Decompensation Events
 

J Gastrointest Cancer. 2021 Jun;52(2):523-528. doi: 10.1007/s12029-020-00409-9.

Yuchen Wang 1, Bashar M Attar 2, Rohit Agrawal 3, Ishaan Vohra 3, Muhammad Zain Farooq 3, Sheeba Ba Aqeel 3, Melchor Demetria 2
 
121.PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease
 

Clin Gastroenterol Hepatol. 2021 Sep;19(9):1979-1981. doi: 10.1016/j.cgh.2020.09.009.Epub 2020 Sep 6.

Grazia Pennisi 1, Rosaria Maria Pipitone 2, Calogero Cammà 2, Vito Di Marco 2, Vincenzo Di Martino 2, Federica Spatola 2, Rossella Zito 2, Antonio Craxì 2, Stefania Grimaudo 2, Salvatore Petta 2
 
122.Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease
 

J Nephrol. 2021 Jun;34(3):649-659. doi: 10.1007/s40620-020-00751-y.Epub 2020 May 21.

Mehmet Kanbay 1, Mustafa C Bulbul 2, Sidar Copur 2, Baris Afsar 3, Alan A Sag 4, Dimitrie Siriopol 5, Masanari Kuwabara 6, Silvia Badarau 5, Adrian Covic 5, Alberto Ortiz 7
 
123.Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease
 

Clin Infect Dis. 2021 Jun 15;72(12):2087-2094.doi: 10.1093/cid/ciaa382.

Lindsay T Fourman 1, Takara L Stanley 1, Isabel Zheng 1, Chelsea S Pan 1, Meghan N Feldpausch 1, Julia Purdy 2, Julia Aepfelbacher 2, Colleen Buckless 3, Andrew Tsao 3, Kathleen E Corey 4, Raymond T Chung 4, Martin Torriani 3, David E Kleiner 5, Colleen M Hadigan 2, Steven K Grinspoon 1
 
124.Dynamic Positron Emission Tomography/Computed Tomography Imaging Correlate of Nonalcoholic Steatohepatitis
 

Clin Gastroenterol Hepatol. 2021 Nov;19(11):2441-2443. doi: 10.1016/j.cgh.2020.10.029.Epub 2020 Oct 17.

Souvik Sarkar 1, Karen E Matsukuma 2, Benjamin Spencer 3, Shuai Chen 4, Kristin A Olson 2, Ramsey D Badawi 3, Michael T Corwin 3, Guobao Wang 5
 
125.Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease
 

Clin Gastroenterol Hepatol. 2021 Jul;19(7):1480-1488.e14. doi: 10.1016/j.cgh.2020.07.030.Epub 2020 Jul 21.

Nandini M Meyersohn 1, Thomas Mayrhofer 2, Kathleen E Corey 3, Daniel O Bittner 4, Pedro V Staziaki 5, Balint Szilveszter 5, Travis Hallett 5, Michael T Lu 5, Stefan B Puchner 6, Tracey G Simon 3, Borek Foldyna 5, Deepak Voora 7, Geoffrey S Ginsburg 7, Pamela S Douglas 8, Udo Hoffmann 5, Maros Ferencik 9
 
126.Liver Steatosis Categorization on Contrast-Enhanced CT Using a Fully Automated Deep Learning Volumetric Segmentation Tool: Evaluation in 1204 Healthy Adults Using Unenhanced CT as a Reference Standard
 

AJR Am J Roentgenol. 2021 Aug;217(2):359-367. doi: 10.2214/AJR.20.24415. Epub 2020 Sep 16.

Perry J Pickhardt 1, Glen M Blake 2, Peter M Graffy 1, Veit Sandfort 3, Daniel C Elton 3, Alberto A Perez 1, Ronald M Summers 3
 
127.Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C
 

Dig Dis Sci. 2021 Jul;66(7):2394-2406. doi: 10.1007/s10620-020-06457-2. Epub 2020 Jul 11.

Jihane N Benhammou 1 2, Andrew M Moon 3, Joseph R Pisegna 4, Feng Su 5, Philip Vutien 5, Cynthia A Moylan 6 7, George N Ioannou 3 8 9
 
128.Genetic And Epigenetic Factors Determining NAFLD Risk
 

Mol Metab. 2021 Aug;50:101111. doi: 10.1016/j.molmet.2020.101111.Epub 2020 Nov 5.

Wenke Jonas 1, Annette Schürmann 2
 
129.Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
 

Clin Gastroenterol Hepatol. 2021 Nov;19(11):22742283.e5.doi:10.1016/j.cgh.2020.08.061. Epub 2020 Aug 31.

Jonathan G Stine 1, Nagambika Munaganuru 2, Abbey Barnard 3, Jennifer L Wang 4, Kellee Kaulback 5, Curtis K Argo 6, Siddarth Singh 3, Kathryn J Fowler 7, Claude B Sirlin 7, Rohit Loomba 8
 
130.Physical Activity, Measured Objectively, Is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease
 

Clin Gastroenterol Hepatol. 2021 Jun;19(6):1240-1247.e5. doi: 10.1016/j.cgh.2020.07.023.Epub 2020 Jul 16.

Donghee Kim 1, Soumya Murag 2, George Cholankeril 3, Amanda Cheung 3, Stephen A Harrison 4, Zobair M Younossi 5, Aijaz Ahmed 3
 
131.Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART)
 

EClinicalMedicine. 2021 Sep 5;40:101116. doi: 10.1016/j.eclinm.2021.101116. eCollection 2021 Oct.

Jenny Bischoff 1, Wenyi Gu 2, Carolynne Schwarze-Zander 1 3, Christoph Boesecke 1 3, Jan-Christian Wasmuth 1 3, Kathrin van Bremen 1, Leona Dold 1 3, Jürgen K Rockstroh 1 3, Jonel Trebicka 2
 
132.Nonalcoholic Fatty Liver Disease Is Common in IBD Patients However Progression to Hepatic Fibrosis by Noninvasive Markers Is Rare
 

Dig Dis Sci. 2021 Sep;66(9):3186-3191. doi: 10.1007/s10620-020-06588-6. Epub 2020 Sep 7.

Gabrielle Ritaccio # 1, Gianna Stoleru # 1, Ameer Abutaleb 2, Raymond K Cross 2, Kirti Shetty 2, Sasan Sakiani 2, Uni Wong 3
 
133.Habitual coffee intake and risk for nonalcoholic fatty liver disease: a two-sample Mendelian randomization study
 

Eur J Nutr. 2021 Jun;60(4):1761-1767. doi: 10.1007/s00394-020-02369-z.Epub 2020 Aug 27.

Yang Zhang # 1, Zhipeng Liu # 2, Tasnim Choudhury 1, Marilyn C Cornelis 3, Wanqing Liu 4 5 6
 
134.Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies
 

Clin Gastroenterol Hepatol. 2021 Jul;19(7):1443-1450.e6. doi: 10.1016/j.cgh.2020.07.065.Epub 2020 Aug 5.

Nabihah Tayob 1, Douglas A Corley 2, Israel Christie 3, Lucy Almers 2, Ahmed K Rahal 4, Peter Richardson 3, Donna L White 3, Jessica Davila 3, Fasiha Kanwal 3, Hashem B El-Serag 5
 
135.External Validation of Four Point-of-Care Noninvasive Scores for Predicting Advanced Hepatic Fibrosis in a Predominantly Hispanic NAFLD Population
 

Dig Dis Sci. 2021 Jul;66(7):2387-2393. doi: 10.1007/s10620-020-06501-1. Epub 2020 Aug 5.

Maya Balakrishnan 1, Aradhna Seth 2 3, Nahir Cortes-Santiago 4, Shilpa Jain 4, Gagan K Sood 5, Hashem B El-Serag 3, Aaron P Thrift 6 7
 
136.Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials
 

Diabetes Metab Res Rev. 2021 Sep;37(6):e3413. doi: 10.1002/dmrr.3413. Epub 2020 Oct 12.

Francisca Dos Santos Coelho 1 2, Marta Borges-Canha 1 2 3, Madalena von Hafe 1 2, João Sérgio Neves 1 2 3, Catarina Vale 1 2, Ana Rita Leite 1 2, Davide Carvalho 3 4, Adelino Leite-Moreira 1 2 5
 
137.Dietary intake of specific amino acids and liver status in subjects with nonalcoholic fatty liver disease: fatty liver in obesity (FLiO) study
 

Eur J Nutr. 2021 Jun;60(4):1769-1780. doi: 10.1007/s00394-020-02370-6. Epub 2020 Aug 28.

Cristina Galarregui 1, Irene Cantero 1, Bertha Araceli Marin-Alejandre 1, J Ignacio Monreal 2 3, Mariana Elorz 2 4, Alberto Benito-Boillos 2 4, José Ignacio Herrero 2 5 6, Víctor de la O 2 7, Miguel Ruiz-Canela 2 7 8, Helen Hermana M Hermsdorff 9, Josefina Bressan 9, Josep A Tur 8 10, J Alfredo Martínez 1 2 8, M Angeles Zulet # 11 12 13, Itziar Abete # 14 15 16
 
138.Multiparametric MRI in Patients With Nonalcoholic Fatty Liver Disease
 

J Magn Reson Imaging. 2021 Jun;53(6):1623-1631. doi: 10.1002/jmri.27292.Epub 2020 Aug 21.

Jelte J Schaapman 1, Maarten E Tushuizen 2, Minneke J Coenraad 2, Hildo J Lamb 1
 
139.Associations Between Reproductive and Hormone-Related Factors and Risk of Nonalcoholic Fatty Liver Disease in a Multiethnic Population
 

Clin Gastroenterol Hepatol. 2021 Jun;19(6):1258-1266.e1. doi: 10.1016/j.cgh.2020.08.012.Epub 2020 Aug 12.

Jun Wang 1, Anna H Wu 1, Frank Z Stanczyk 2, Jacqueline Porcel 3, Mazen Noureddin 4, Norah A Terrault 5, Lynne R Wilkens 6, Veronica Wendy Setiawan 7
 
140.Prevalence of Fatty Liver Disease and Fibrosis Detected by Transient Elastography in Adults in the United States, 2017-2018
 

Clin Gastroenterol Hepatol. 2021 Jul;19(7):1499-1501.e2. doi: 10.1016/j.cgh.2020.08.017.Epub 2020 Aug 12.

Donghee Kim 1, George Cholankeril 2, Rohit Loomba 3, Aijaz Ahmed 2
 
141.Liver Stiffness by Magnetic Resonance Elastography Predicts Future Cirrhosis, Decompensation, and Death in NAFLD
 

Clin Gastroenterol Hepatol. 2021 Sep;19(9):1915-1924.e6. doi: 10.1016/j.cgh.2020.09.044.Epub 2020 Sep 30.

Tolga Gidener 1, Omar T Ahmed 1, Joseph J Larson 2, Kristin C Mara 2, Terry M Therneau 2, Sudhakar K Venkatesh 3, Richard L Ehman 3, Meng Yin 3, Alina M Allen 4
 
142.Antioxidant activity of Hydroxytyrosol and Vitamin E reduces systemic inflammation in children with paediatric NAFLD
 

Dig Liver Dis. 2021 Sep;53(9):1154-1158. doi: 10.1016/j.dld.2020.09.021. Epub 2020 Oct 13.

Antonella Mosca 1, Annalisa Crudele 2, Antonella Smeriglio 3, Maria Rita Braghini 2, Nadia Panera 2, Donatella Comparcola 4, Arianna Alterio 4, Maria Rita Sartorelli 4, Giulia Tozzi 1, Massimiliano Raponi 5, Domenico Trombetta 3, Anna Alisi 6
 
143.Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
 

Gut. 2021 Jul;70(7):1375-1382. doi: 10.1136/gutjnl-2020-322786. Epub 2020 Oct 9.

Tracey G Simon 1 2 3, Bjorn Roelstraete 4, Hamed Khalili 1 2 3, Hannes Hagström 5, Jonas F Ludvigsson 6 7 8 9 10
 
144.Testosterone is Associated With Nonalcoholic Steatohepatitis and Fibrosis in Premenopausal Women With NAFLD
 

Clin Gastroenterol Hepatol. 2021 Jun;19(6):1267-1274.e1. doi: 10.1016/j.cgh.2020.09.045.Epub 2020 Oct 1.

Monika A Sarkar 1, Ayako Suzuki 2, Manal F Abdelmalek 2, Katherine P Yates 3, Laura A Wilson 3, Nathan M Bass 4, Ryan Gill 5, Marcelle Cedars 6, Norah Terrault 7, NASH Clinical Research Network
 
145.Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
 

Mol Metab. 2021 Aug;50:101122. doi: 10.1016/j.molmet.2020.101122.Epub 2020 Nov 19.

Kalliopi Pafili 1, Michael Roden 2
 
146.The Clinical Spectrum and Diagnosis of Oxaliplatin Liver Injury in the Era of Nonalcoholic Fatty Liver Disease
 

Clin Gastroenterol Hepatol. 2021 Oct;19(10):2199-2201. doi: 10.1016/j.cgh.2020.09.038.Epub 2020 Sep 30.

Hannah P Kim 1, Victor Navarro 2, Steven Zacks 3, Joseph Odin 4, David E Kleiner 5, Paul H Hayashi 6, Drug-Induced Liver Injury Network Investigators
 
147.Hepatic Steatosis Is Associated with Increased Disease Severity and Liver Injury in Coronavirus Disease-19
 

Dig Dis Sci. 2021 Sep;66(9):3192-3198. doi: 10.1007/s10620-020-06618-3. Epub 2020 Sep 27.

Vincent L Chen 1, Fadi Hawa 2, Jeffrey A Berinstein 3, Chanakyaram A Reddy 3, Ihab Kassab 4, Kevin D Platt 3, Chia-Yang Hsu 3, Calen A Steiner 3, Jeremy Louissaint 3, Naresh T Gunaratnam 5, Pratima Sharma 3
 
148.ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis
 

Hepatology. 2021 Jun;73(6):2238-2250. doi: 10.1002/hep.31576. Epub 2021 Apr 19.

Luis Calzadilla-Bertot 1, Eduardo Vilar-Gomez 2 3, Vincent Wai-Sun Wong 4, Manuel Romero-Gomez 3, Rocio Aller-de la Fuente 5, Grace Lai-Hung Wong 4, Marlen Castellanos 6, Mohammed Eslam 7, Archita P Desai 2, Gary P Jeffrey 1 8, Jacob George 7, Naga Chalasani 2, Leon A Adams 1 8
 
149.Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard
 

Clin Infect Dis. 2021 Jun 15;72(12):2124-2131. doi: 10.1093/cid/ciaa429.

Veeral H Ajmera 1 2, Edward R Cachay 3, Christian B Ramers 4, Shirin Bassirian 1, Seema Singh 1, Richele Bettencourt 1, Lisa Richards 1, Gavin Hamilton 5, Michael Middleton 5, Katie Fowler 5, Claude Sirlin 5, Rohit Loomba 1 2 6
 
150.Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease
 

Clin Gastroenterol Hepatol. 2021 Oct;19(10):2202-2204. doi: 10.1016/j.cgh.2020.09.039.Epub 2020 Sep 30.

Samarth Patel 1, Mohammad Bilal Siddiqui 2, Jose Hernandez Roman 3, Emily Zhang 4, Emily Lee 4, Steve Shen 4, Masoud Faridnia 3, Robert J Mintini 5, Sherry Boyett 5, Michael O Idowu 6, Arun J Sanyal 1, Velimir A Luketic 1, Mohammad Shadab Siddiqui 1
 
151.Enhanced Liver Fibrosis Score Can Be Used to Predict Liver-Related Events in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis
 

Clin Gastroenterol Hepatol. 2021 Jun;19(6):1292-1293.e3. doi: 10.1016/j.cgh.2020.06.070.Epub 2020 Jul 3.

Vijay S Are 1, Raj Vuppalanchi 1, Eduardo Vilar-Gomez 1, Naga Chalasani 2
 
152.NAFLD and cardiovascular diseases: a clinical review
 

Clin Res Cardiol. 2021 Jul;110(7):921-937. doi: 10.1007/s00392-020-01709-7.Epub 2020 Jul 21.

Philipp Kasper 1, Anna Martin 1, Sonja Lang 2, Fabian Kütting 1, Tobias Goeser 1, Münevver Demir 3, Hans-Michael Steffen 4 5
 
153.The relationship between excessive dietary fructose consumption and pediatric fatty liver disease
 

Pediatr Obes. 2021 Jun;16(6):e12759. doi: 10.1111/ijpo.12759. Epub 2020 Dec 11.

Johanna K DiStefano 1, Gabriel Q Shaibi 2
 
154.Liver disease in obesity and underweight: the two sides of the coin. A narrative review
 

Eat Weight Disord. 2021 Oct;26(7):2097-2107. doi: 10.1007/s40519-020-01060-w.Epub 2020 Nov 4.

Renata Risi 1, Dario Tuccinardi 2, Stefania Mariani 1, Carla Lubrano 1, Silvia Manfrini 3, Lorenzo Maria Donini 1, Mikiko Watanabe 1
 
155.Breaking Down Barriers to Physical Activity in Patients with Nonalcoholic Fatty Liver Disease
 

Dig Dis Sci. 2021 Oct;66(10):3604-3611. doi: 10.1007/s10620-020-06673-w. Epub 2020 Oct 23.

Jonathan G Stine 1 2 3 4 5, Christopher Soriano 6, Ian Schreibman 7 8, Gloriany Rivas 7, Breianna Hummer 7, Esther Yoo 6, Kathryn Schmitz 9 10 11 12, Christopher Sciamanna 9 10 6
 
156.Incident Dementia in Elderly Patients with Nonalcoholic Fatty Liver Disease in Germany
 

Dig Dis Sci. 2021 Sep;66(9):3179-3185. doi: 10.1007/s10620-020-06644-1. Epub 2020 Oct 10.

Christian Labenz 1 2 3, Karel Kostev 4, Leonard Kaps 1 3, Peter R Galle 1 2, Jörn M Schattenberg 5 6 7
 
157.Predicting Non-Alcoholic Fatty Liver Disease for Adults Using Practical Clinical Measures: Evidence from the Multi-ethnic Study of Atherosclerosis
 

J Gen Intern Med. 2021 Sep;36(9):2648-2655. doi: 10.1007/s11606-020-06426-5.Epub 2021 Jan 26.

Luis A Rodriguez 1, Stephen C Shiboski 2, Patrick T Bradshaw 3, Alicia Fernandez 4, David Herrington 5, Jingzhong Ding 6, Ryan D Bradley 7, Alka M Kanaya 2 4
 
158.Increased Body Mass Index and Type 2 Diabetes Are the Main Predictors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Liver Biopsies of Patients With Human Immunodeficiency Virus Monoinfection
 

Clin Infect Dis. 2021 Oct 5;73(7):e2184-e2193. doi: 10.1093/cid/ciaa1302.

James B Maurice 1 2, Robert Goldin 3, Andrew Hall 4, Jennifer C Price 5, Giada Sebastiani 6 7, Caryn G Morse 8, Laura Iogna Prat 2, Hugo Perazzo 9, Lucy Garvey 10, Patrick Ingiliz 11, Giovanni Guaraldi 12, Emmanouil Tsochatzis 2 13, Maud Lemoine 1
 
159.Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease
 

Clin Infect Dis. 2021 Aug 16;73(4):621-630.doi: 10.1093/cid/ciab019.

Takara L Stanley 1, Lindsay T Fourman 1, Lai Ping Wong 2, Ruslan Sadreyev 2, James M Billingsley 3, Meghan N Feldpausch 1, Isabel Zheng 1, Chelsea S Pan 1, Autumn Boutin 1, Hang Lee 4, Kathleen E Corey 5, Martin Torriani 6, David E Kleiner 7, Raymond T Chung 5, Colleen M Hadigan 8, Steven K Grinspoon 1
 
160.Evolution of Non-alcoholic Fatty Liver Disease (NAFLD) Biomarkers in Response to Weight Loss 1 Year After Bariatric Surgery-a Post Hoc Analysis of the FibroTest Prospective Study
 

Obes Surg. 2021 Aug;31(8):3548-3556. doi: 10.1007/s11695-021-05402-0. Epub 2021 Apr 12.

Tatiana Codjia 1, Lionel Rebibo 2, Arnaud François 3, Carole Lagnel 4, Emmanuel Huet 5, Soumeya Bekri 4, François Pattou 6, Jean-Marc Régimbeau 2, Lilian Schwarz 5
 
161.Community screening identifies undiagnosed chronic liver disease in high-risk populations
 

Gastroenterol Hepatol. 2021 Aug;36(8):2255-2260. doi: 10.1111/jgh.15473. Epub 2021 Mar 17.

Salim Maher 1 2, Lisa Dowdell 1, Ling Zhang 1, Amany Zekry 1 2
 
162.Longitudinal associations of total and trunk fat in childhood and adolescence and risk of hepatic steatosis at 24 years
 

Pediatr Obes. 2021 Aug;16(8):e12773. doi: 10.1111/ijpo.12773. Epub 2021 Feb 8.

Catherine C Cohen 1, Ahlia Sekkarie 2, Janet Figueroa 1, Scott E Gillespie 1, Miriam B Vos 1 2 3, Jean A Welsh 1 2 3
 
163.Omega-3 Use for the Treatment of Hypertriglyceridemia, Low High-Density Lipoprotein Cholesterol Levels, and Nonalcoholic Fatty Liver Disease in Children with Obesity
 

Child Obes. 2021 Jul;17(5):357-364. doi: 10.1089/chi.2021.0047. Epub 2021 Apr 12.

Kristin M W Stackpole 1, Nicholas J Ollberding 2 3, Laurie A Smith 2, Paula Casson 4, Shelley Kirk 1 3, Robert Siegel 1 3
 
164.Unhealthy Eating, Psychopathology, and Nonalcoholic Fatty Liver Disease in Youth Presenting for Bariatric Surgery
 

J Pediatr Gastroenterol Nutr. 2021 Jul 27. doi: 10.1097/MPG.0000000000003253.Online ahead of print.

Sanita L Ley 1, Meg H Zeller, Jennifer Reiter-Purtill, David E Kleiner, John Dixon, Stavra Xanthakos, Teen View Study Group and in collaboration with the Teen-LABS Consortium
 
165.Factors associated with engagement and adherence to a low-energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease
 

BMJ Open Gastroenterol. 2021 Jul;8(1):e000678. doi: 10.1136/bmjgast-2021-000678.

Jadine Scragg 1 2, Kate Hallsworth 1 3, Guy Taylor 4, Sophie Cassidy 4, Laura Haigh 1 3, Marie Boyle 1 3, Quentin Anstee 1 3, Stuart McPherson 1 3, Leah Avery 5 6
 
166.The role of zinc in the prevention and treatment of nonalcoholic fatty liver disease
 

Metabol Open. 2021 Jun 29;11:100105. doi: 10.1016/j.metop.2021.100105. eCollection 2021 Sep.

Mary Barbara 1 2, Ayse L Mindikoglu 1 2
 
167.Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention
 

J Hepatol. 2021 Jul 30;S0168-8278(21)01954-1. doi: 10.1016/j.jhep.2021.07.025.Online ahead of print.

Naomi F Lange 1, Pompilia Radu 2, Jean-François Dufour 2
 
168.Meta-analysis of trials in non-alcoholic fatty liver disease with therapeutic interventions for metabolic syndrome
 

Diabetes Metab Syndr. 2021 Jul 28;15(5):102232.doi: 10.1016/j.dsx.2021.102232.Online ahead of print.

Stewart G Albert 1, Emily M Wood 2
 
169.Preparing for the NASH epidemic: A call to action
 

Obesity (Silver Spring). 2021 Sep;29(9):1401-1412. doi: 10.1002/oby.23250.Epub 2021 Aug 8.

Fasiha Kanwal 1, Jay H Shubrook 2, Zobair Younossi 3, Yamini Natarajan 4, Elisabetta Bugianesi 5, Mary E Rinella 6, Stephen A Harrison 7, Christos Mantzoros 8, Kim Pfotenhauer 9, Samuel Klein 10, Robert H Eckel 11, Davida Kruger 12, Hashem El-Serag 4, Kenneth Cusi 13
 
170.A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis
 

Hepatology. 2021 Aug 1. doi: 10.1002/hep.32087. Online ahead of print.

Jaime Bosch 1 2, Chuhan Chung 3, Oscar M Carrasco-Zevallos 4, Stephen A Harrison 5, Manal F Abdelmalek 6, Mitchell L Shiffman 7, Don C Rockey 8, Zahil Shanis 4, Dinkar Juyal 4, Harsha Pokkalla 4, Quang Huy Le 4, Murray Resnick 4, Michael Montalto 4, Andrew H Beck 4, Ilan Wapinski 4, Ling Han 3, Catherine Jia 3, Zachary Goodman 9, Nezam Afdhal 10, Robert P Myers 3, Arun J Sanyal 11
 
171.Association of Body Composition and Sarcopenia with NASH in Obese Patients
 

J Clin Med. 2021 Aug 3;10(15):3445. doi: 10.3390/jcm10153445.

Sophia Marie-Therese Schmitz 1, Lena Schooren 1, Andreas Kroh 1, Alexander Koch 2, Christine Stier 3, Ulf Peter Neumann 1 4, Tom Florian Ulmer 1 4, Patrick Hamid Alizai 1
 
172.Insulin resistance and NAFLD may influence memory performance in obese patients with prediabetes or newly-diagnosed type 2 diabetes
 

Nutr Metab Cardiovasc Dis. 2021 Aug 26;31(9):2685-2692. doi: 10.1016/j.numecd.2021.05.027.Epub 2021 Jun 6.

Francesco Vadini 1, Paola G Simeone 2, Giovambattista Desideri 3, Rossella Liani 2, Romina Tripaldi 2, Sonia Ciotti 2, Armando Tartaro 4, Maria T Guagnano 2, Augusto Di Castelnuovo 5, Francesco Cipollone 2, Agostino Consoli 2, Francesca Santilli 6
 
173.Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality
 

J Hepatol. 2021 Jul 3;S0168-8278(21)01883-3. doi: 10.1016/j.jhep.2021.06.034.Online ahead of print.

Tracey G Simon 1, Bjorn Roelstraete 2, Kayla Hartjes 3, Uzma Shah 3, Hamed Khalili 4, Henrik Arnell 5, Jonas F Ludvigsson 6
 
174.Internal medicine hospitalizations and liver disease: a comparative disease burden analysis of a multicentre cohort
 

Aliment Pharmacol Ther. 2021 Sep;54(5):689-698.doi: 10.1111/apt.16488. Epub 2021 Jun 28.

Surain B Roberts 1 2, Bettina E Hansen 1 2, Saeha Shin 3, Lusine Abrahamyan 1 4, Lauren Lapointe-Shaw 5 6, Harry L A Janssen 2, Fahad Razak 3 5, Amol A Verma 3 5, Gideon M Hirschfield 1 2
 
175.Associations Among Adipose Tissue Immunology, Inflammation, Exosomes and Insulin Sensitivity in People With Obesity and Nonalcoholic Fatty Liver Disease
 

Gastroenterology. 2021 Sep;161(3):968-981.e12. doi: 10.1053/j.gastro.2021.05.008.Epub 2021 May 15.

Anja Fuchs 1, Dmitri Samovski 2, Gordon I Smith 2, Vincenza Cifarelli 2, Sarah S Farabi 2, Jun Yoshino 2, Terri Pietka 2, Shin-Wen Chang 1, Sarbani Ghosh 1, Terence M Myckatyn 1, Samuel Klein 3
 
176.A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease
 

Clin Gastroenterol Hepatol. 2021 Jul 3;S1542-3565(21)00719-9.

 doi: 10.1016/j.cgh.2021.06.048.Online ahead of print.

Zobair M Younossi 1, Janus P Ong 2, Hirokazu Takahashi 3, Yusuf Yilmaz 4, Yuichiro Eguchi 5, Mohamed El Kassas 6, Maria Buti 7, Moisés Diago 8, Ming-Hua Zheng 9, Jian-Gao Fan 10, Ming-Lung Yu 11, Vincent Wai-Sun Wong 12, Khalid Alswat 13, Wah-Kheong Chan 14, Nahum Mendez-Sanchez 15, Patrizia Burra 16, Elisabetta Bugianesi 17, Ajay K Duseja 18, Jacob George 19, George V Papatheodoridis 20, Hamid Saeed 21, Laurent Castera 22, Marco Arrese 23, Marcelo Kugelmas 24, Manuel Romero-Gomez 25, Saleh Alqahtani 26, Mariam Ziayee 27, Brian Lam 28, Issah Younossi 27, Andrei Racila 28, Linda Henry 27, Maria Stepanova 27, Global NASH Council
 
177.Exercise Training Reverses Gut Dysbiosis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis: A Proof of Concept Study
 

Clin Gastroenterol Hepatol. 2021 Aug;19(8):1723-1725. doi: 10.1016/j.cgh.2020.08.063.Epub 2020 Aug 31.

Alexa Hughes 1, Jessica Dahmus 2, Gloriany Rivas 2, Breianna Hummer 2, Jeremy R Chen See 3, Justin R Wright 3, Regina Lamendella 4, Kathryn H Schmitz 5, Christopher Sciamanna 6, Mack Ruffin 7, Andrew D Patterson 8, Rohit Loomba 9, Jonathan G Stine 10
 
178.Microbiota-Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling
 

Hepatology. 2021 Aug;74(2):704-722. doi: 10.1002/hep.31755.

Fanta Barrow # 1, Saad Khan # 2 3, Gavin Fredrickson 1, Haiguang Wang 1, Katrina Dietsche 1, Preethy Parthiban 1, Sacha Robert 1, Thomas Kaiser 4, Shawn Winer 2, Adam Herman 5, Oyedele Adeyi 6, Marialena Mouzaki 7, Alexander Khoruts 8 9, Kristin A Hogquist 6 9, Christopher Staley 4, Daniel A Winer 2 3 10, Xavier S Revelo 1 9
 
179.Training of computational algorithms to predict NAFLD activity score and fibrosis stage from liver histopathology slides
 

Comput Methods Programs Biomed. 2021 Aug;207:106153. doi: 10.1016/j.cmpb.2021.106153.Epub 2021 May 8.

Hui Qu 1, Carlos D Minacapelli 2, Christopher Tait 3, Kapil Gupta 4, Abhishek Bhurwal 5, Carolyn Catalano 6, Randa Dafalla 7, Dimitris Metaxas 8, Vinod K Rustgi 9
 
180.Effect of exercise on cardiometabolic health of adults with overweight or obesity: Focus on blood pressure, insulin resistance, and intrahepatic fat-A systematic review and meta-analysis
 

Obes Rev. 2021 Jul;22 Suppl 4(Suppl 4):e13269. doi: 10.1111/obr.13269. Epub 2021 May 6.

Francesca Battista 1, Andrea Ermolao 1, Marleen A van Baak 2, Kristine Beaulieu 3, John E Blundell 3, Luca Busetto 4 5, Eliana V Carraça 6, Jorge Encantado 7, Dror Dicker 4 8, Nathalie Farpour-Lambert 4 9, Adriyan Pramono 2, Alice Bellicha 10 11, Jean-Michel Oppert 12
 
181.Liver Fibrosis is Associated with Ischemic Stroke Risk in Women but not Men: The REGARDS Study
 

JStrokeCerebrovascDis. 2021Jul;30(7):105788doi:10.1016/j.jstrokecerebrovasdis.2021.105788. Epub 2021 Apr 16.

Neal S Parikh 1, Insu Koh 2, Lisa B VanWagner 3, Mitchell S V Elkind 4, Neil A Zakai 5, Mary Cushman 5
 
182.NAFLD and renal function in children: is there a genetic link?
 

Expert Rev Gastroenterol Hepatol. 2021 Sep;15(9):975-984.doi: 10.1080/17474124.2021.1906649. Epub 2021 Apr 14.

Anna Di Sessa 1, Stefano Guarino 1, Antonio Paride Passaro 1, Laura Liguori 1, Giuseppina Rosaria Umano 1, Grazia Cirillo 1, Emanuele Miraglia Del Giudice 1, Pierluigi Marzuillo 1
 
183.Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
 

Semin Liver Dis. 2021 Jul 21. doi: 10.1055/s-0041-1732354. Online ahead of print.

Sabine Kahl 1 2 3, Jennifer Pützer 1 2, Michael Roden 1 2 3
 
184.AST to Platelet Ratio Index (APRI) is an easy-to-use predictor score for cardiovascular risk in metabolic subjects
 

Sci Rep. 2021 Jul 21;11(1):14834. doi: 10.1038/s41598-021-94277-3.

Carlo De Matteis 1, Marica Cariello 1, Giusi Graziano 1, Stefano Battaglia 2 3, Patrizia Suppressa 2, Giuseppina Piazzolla 2, Carlo Sabbà 2, Antonio Moschetta 4 5
 
185.How will NAFLD change the liver transplant landscape in the 2020s?
 

Clin Res Hepatol Gastroenterol. 2021 Jul 23;101759.doi: 10.1016/j.clinre.2021.101759. Online ahead of print.

François Villeret 1, Jérôme Dumortier 2, Domitille Erard-Poinsot 3
 
186.Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications
 

Diabetes Obes Metab. 2021 Jul 29. doi: 10.1111/dom.14484. Online ahead of print.

Christopher D Byrne 1 2, Giovanni Targher 3
 
187.Maternal obesity increases the risk and severity of NAFLD in offspring
 

J Hepatol. 2021 Jul 18;S0168-8278(21)01899-7. doi: 10.1016/j.jhep.2021.06.045.Online ahead of print.

Hannes Hagström 1, Tracey G Simon 2, Bjorn Roelstraete 3, Olof Stephansson 4, Jonas Söderling 5, Jonas F Ludvigsson 6
 
188.Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology
 

J Hepatol. 2021 Jul 29;S0168-8278(21)01948-6. doi: 10.1016/j.jhep.2021.07.018.Online ahead of print.

Gennaro D'Amico 1, Luigi Maruzzelli 2, Aldo Airoldi 3, Ioannis Petridis 4, Giulia Tosetti 5, Antonio Rampoldi 6, Mario D'Amico 7, Roberto Miraglia 2, Stella De Nicola 3, Vincenzo La Mura 8, Marco Solcia 6, Riccardo Volpes 4, Giovanni Perricone 3, Cristiano Sgrazzutti 9, Angelo Vanzulli 9, Massimo Primignani 5, Angelo Luca 2, Giuseppe Malizia 10, Alessandro Federico 11, Marcello Dallio 11, Angelo Andriulli 12, Angelo Iacobellis 12, Luigi Addario 13, Matteo Garcovich 14, Antonio Gasbarrini 14, Luchino Chessa 15, Francesco Salerno 16, Giulia Gobbo 16, Manuela Merli 17, Lorenzo Ridola 18, Gianluca Svegliati Baroni 19, Giuseppe Tarantino 19, Nicola Caporaso 20, Filomena Morisco 20, Pietro Pozzoni 21, Agostino Colli 21, Luca Saverio Belli 3
 
189.Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life
 

Clin Gastroenterol Hepatol. 2021 Jul 27;S1542-3565(21)00821-1. doi: 10.1016/j.cgh.2021.07.039.Online ahead of print.

Zobair M Younossi 1, Maria Stepanova 2, Rebecca A Taub 3, Jordan Mark Barbone 3, Stephen A Harrison 4
 
190.Zonation in NASH - A key paradigm for understanding pathophysiology and clinical outcomes
 

Liver Int. 2021 Jul 30. doi: 10.1111/liv.15025. Online ahead of print.

Jonathan B Steinman 1, Marcela A Salomao 2, Utpal B Pajvani 3
 
191.Diet and exercise in NAFLD/NASH: Beyond the obvious
 

Liver Int. 2021 Jul 30. doi: 10.1111/liv.15024. Online ahead of print.

Georg Semmler 1, Christian Datz 2, Thomas Reiberger 1, Michael Trauner 1
 
192.The impact of alteration in gut microbiome in the pathogenesis of nonalcoholic fatty liver disease
 

Curr Opin Infect Dis. 2021 Jul 15. doi: 10.1097/QCO.0000000000000759. Online ahead of print.

Jake S Jacob 1, Aijaz Ahmed, George Cholankeril
 
193.FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption
 

Cell Metab. 2021 Aug 3;33(8):1671-1684.e4. doi: 10.1016/j.cmet.2021.06.012. Epub 2021 Jul 15.

Bethan L Clifford 1, Leslie R Sedgeman 1, Kevin J Williams 2, Pauline Morand 3, Angela Cheng 3, Kelsey E Jarrett 1, Alvin P Chan 1, Madelaine C Brearley-Sholto 1, Annika Wahlström 4, Julianne W Ashby 1, William Barshop 3, James Wohlschlegel 3, Anna C Calkin 5, Yingying Liu 6, Anders Thorell 7, Peter J Meikle 8, Brian G Drew 9, Julia J Mack 10, Hanns-Ulrich Marschall 4, Elizabeth J Tarling 11, Peter A Edwards 12, Thomas Q de Aguiar Vallim 13
 
194.Binge-eating disorder is associated with an unfavorable body mass composition in patients with non-alcoholic fatty liver disease
 

Int J Eat Disord. 2021 Jul 17. doi: 10.1002/eat.23584. Online ahead of print.

Roberta Forlano 1, Christopher Harlow 1, Benjamin H Mullish 1, Mark R Thursz 1, Pinelopi Manousou 1, Michael Yee 2
 
195.Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study
 

Clin Gastroenterol Hepatol. 2021 Jul 13;S1542-3565(21)00747-3. doi: 10.1016/j.cgh.2021.07.016.Online ahead of print.

Omar T Ahmed 1, Tolga Gidener 1, Kristin C Mara 2, Joseph J Larson 2, Terry M Therneau 2, Alina M Allen 3
 
196.Metabolic surgery may protect against admission for COVID-19 in persons with nonalcoholic fatty liver disease
 

Surg Obes Relat Dis. 2021 Jun 29;S1550-7289(21)00264-1. doi: 10.1016/j.soard.2021.05.029.Online ahead of print

Christopher J Tignanelli 1, Carolyn T Bramante 2, Nirjhar Dutta 2, Leonardo Tamariz 3, Michael G Usher 2, Sayeed Ikramuddin 4
 
197.Bariatric surgery proves long-term benefit in patients with cirrhosis
 

Gastroenterol Rep (Oxf). 2020 Nov 24;9(3):252-256.doi: 10.1093/gastro/goaa057.eCollection 2021 Jun.

Manhal Izzy 1, Mounika Angirekula 2, Barham K Abu Dayyeh 2, Fateh Bazerbachi 3, Kymberly D Watt 2
 
198.Association of Serum Bilirubin Level with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study of 1672 Obese Children
 

J Clin Med. 2021 Jun 25;10(13):2812. doi: 10.3390/jcm10132812.

Cristina Bellarosa 1, Giorgio Bedogni 1, Annalisa Bianco 1 2, Sabrina Cicolini 3, Diana Caroli 3, Claudio Tiribelli 1, Alessandro Sartorio 3 4
 
199.Physical Activity Is Associated With Nonalcoholic Fatty Liver Disease and Significant Fibrosis Measured by FibroScan
 

Clin Gastroenterol Hepatol. 2021 Jun 29;S1542-3565(21)00693-5.doi: 10.1016/j.cgh.2021.06.029. Online ahead of print.

Donghee Kim 1, Peter Konyn 2, George Cholankeril 3, Aijaz Ahmed 4
 
200.The relationship between frailty and cirrhosis etiology: From the Functional Assessment in Liver Transplantation (FrAILT) Study
 

Liver Int. 2021 Jul 5.doi: 10.1111/liv.15006. Online ahead of print.

Chelsea Q Xu 1, Yara Mohamad 1, Matthew R Kappus 2, Brian Boyarsky 3, Daniel R Ganger 4, Michael L Volk 5, Robert S Rahimi 6, Andres Duarte-Rojo 7, Mara McAdams-DeMarco 3 8, Dorry L Segev 3 8, Daniela P Ladner 9 10, Elizabeth C Verna 11, Joshua Grab 12, Monica Tincopa 13, Michael A Dunn 7, Jennifer C Lai 1
 
201.Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
 

Front Endocrinol (Lausanne). 2021 Jun 17;12:635556. doi: 10.3389/fendo.2021.635556.eCollection 2021.

Qiong Wei 1 2, Xinyue Xu 1 2, Li Guo 1 2, Jia Li 3, Ling Li 1 2
 
202.Three Different Genetic Risk Scores Based on Fatty Liver Index, Magnetic Resonance Imaging and Lipidomic for a Nutrigenetic Personalized Management of NAFLD: The Fatty Liver in Obesity Study
 

Diagnostics (Basel). 2021 Jun 13;11(6):1083. doi: 10.3390/diagnostics11061083.

Nuria Perez-Diaz-Del-Campo 1 2, Jose I Riezu-Boj 2 3, Bertha Araceli Marin-Alejandre 1 2, J Ignacio Monreal 3 4, Mariana Elorz 3 5, José Ignacio Herrero 3 6 7, Alberto Benito-Boillos 3 5, Fermín I Milagro 1 2 3 8, Josep A Tur 8 9, Itziar Abete 1 2 3 8, M Angeles Zulet 1 2 3 8, J Alfredo Martinez 1 2 3 8
 
203.Embedding assessment of liver fibrosis into routine diabetic review in primary care
 

HEP Rep. 2021 Apr 22;3(4):100293. doi: 10.1016/j.jhepr.2021.100293. eCollection 2021 Aug.

Dina Mansour 1 2, Allison Grapes 1, Marc Herscovitz 3, Paul Cassidy 4, Jonathan Vernazza 1, Andrea Broad 5, Quentin M Anstee 2 6, Stuart McPherson 2 6
 
204.Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes
 

J Clin Endocrinol Metab. 2021 Jun 30;dgab417. doi: 10.1210/clinem/dgab417.Online ahead of print.

Fernando Bril 1 2, Michael J McPhaul 3, Srilaxmi Kalavalapalli 2, Romina Lomonaco 2, Diana Barb 2, Meagan E Gray 4, Dov Shiffman 3, Charles M Rowland 3, Kenneth Cusi 2 5
 
205.Patient disease knowledge, attitudes and behaviours related to non-alcoholic fatty liver disease: a qualitative study
 

BMJ Open Gastroenterol. 2021 Jun;8(1):e000634. doi: 10.1136/bmjgast-2021-000634.

Monica A Tincopa 1, Jane Wong 2, Michael Fetters 3, Anna S Lok 2
 
206.NAFLD and alcohol-related liver disease will be responsible for almost all new diagnoses of cirrhosis in Canada by 2040
 

Hepatology. 2021 Jun 26. doi: 10.1002/hep.32032. Online ahead of print.

Jennifer A Flemming 1 2 3 4, Maya Djerboua 2, Patti A Groome 2 3 4, Christopher M Booth 2 3 4, Norah A Terrault 5
 
207.TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial
 

Gastroenterology. 2021 Jul 20;S0016-5085(21)03276-5. doi: 10.1053/j.gastro.2021.07.025.Online ahead of print.

Rohit Loomba 1, Rizwana Mohseni 2, K Jean Lucas 3, Julio A Gutierrez 4, Robert G Perry 5, James F Trotter 6, Robert S Rahimi 6, Stephen A Harrison 7, Veeral Ajmera 8, Jeffrey D Wayne 9, Marie O'Farrell 10, William McCulloch 10, Katharine Grimmer 10, Mary Rinella 11, Vincent Wai-Sun Wong 12, Vlad Ratziu 13, Gregory J Gores 14, Brent A Neuschwander-Tetri 15, George Kemble 10
 
208.Preparing for the NASH epidemic: A call to action
 

Metabolism. 2021 Jul 6;154822. doi: 10.1016/j.metabol.2021.154822. Online ahead of print.

Fasiha Kanwal 1, Jay H Shubrook 2, Zobair Younossi 3, Yamini Natarajan 4, Elisabetta Bugianesi 5, Mary E Rinella 6, Stephen A Harrison 7, Christos Mantzoros 8, Kim Pfotenhauer 9, Samuel Klein 10, Robert H Eckel 11, Davida Kruger 12, Hashem El-Serag 4, Kenneth Cusi 13
 
209.Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches
 

Nutrients. 2021 Jun 8;13(6):1977. doi: 10.3390/nu13061977.

Angelo Armandi 1 2, Jörn M Schattenberg 2 3
 
210.Pediatric nonalcoholic fatty liver disease - a changing diagnostic paradigm
 

Rom J Morphol Embryol. Oct-Dec 2020;61(4):1023-1031. doi: 10.47162/RJME.61.4.04.

Laura Mihaela Trandafir 1, Otilia Elena Frasinariu, Maria Magdalena Leon-Constantin, Stefan Chiriac, Mioara Florentina Trandafirescu, Ingrith Crenguta Miron, Alina Costina Luca, Alin Constantin Iordache, Elena Cojocaru
 
211.Conventional ultrasound for diagnosis of hepatic steatosis is better than believed
 

Z Gastroenterol. 2021 Jun 25. doi: 10.1055/a-1491-1771. Online ahead of print.

Christoph F Dietrich 1, Long Shi 2, Axel Löwe 1, Yi Dong 3, Andrej Potthoff 4, Zeno Sparchez 5, Andreas Teufel 6, Sabine Guth 7, Jonas Koch 1, Richard G Barr 8, Xin-Wu Cui 9
 
212.Defining comprehensive models of care for NAFLD
 

Nat Rev Gastroenterol Hepatol. 2021 Jun 25. doi: 10.1038/s41575-021-00477-7.Online ahead of print.

Jeffrey V Lazarus 1 2, Quentin M Anstee 3 4, Hannes Hagström 5, Kenneth Cusi 6, Helena Cortez-Pinto 7, Henry E Mark 8, Michael Roden 9 10 11, Emmanuel A Tsochatzis 12 13, Vincent Wai-Sun Wong 14, Zobair M Younossi 15, Shira Zelber-Sagi 16 17, Manuel Romero-Gómez # 18, Jörn M Schattenberg # 19
 
213.Impact of Fibrosis-4 Index Prior to COVID-19 on Outcomes in Patients at Risk of Non-alcoholic Fatty Liver Disease
 

Dig Dis Sci. 2021 Jun 26;1-7. doi: 10.1007/s10620-021-07120-0. Online ahead of print.

Mohamed A Elfeki 1 2 3, Julian Robles 1 2, Zaheer Akhtar 1 2, Fauzia Ullah 1 2, Ice Ganapathiraju 1 2, Calvin Tran 4 5, Casey Inman 4 5, Simon M Collin 6, Rossana Rosa 7
 
214.COVID-19 and pediatric fatty liver disease: Is there interplay?
 

World J Gastroenterol. 2021 Jun 14;27(22):3064-3072.doi: 10.3748/wjg.v27.i22.3064.

Anna Di Sessa 1, Francesca Lanzaro 2, Sarah Zarrilli 2, Vittorio Picone 2, Stefano Guarino 2, Emanuele Miraglia Del Giudice 2, Pierluigi Marzuillo 2
 
215.Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
 

Hepatol Commun. 2021 May 12;5(7):1201-1211. doi: 10.1002/hep4.1710. eCollection 2021 Jul.

Zobair M Younossi 1 2, Maria Stepanova 3, Mazen Noureddin 4, Kris V Kowdley 5, Simone I Strasser 6, Anita Kohli 7, Peter Ruane 8, Mitchell L Shiffman 9, Aasim Sheikh 10, Nadege Gunn 11, Stephen H Caldwell 12, Ryan S Huss 13, Robert P Myers 13, Vincent Wai-Sun Wong 14, Naim Alkhouri 15, Zachary Goodman 1 2, Rohit Loomba 4
 
216.Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis
 

Clin Gastroenterol Hepatol. 2021 Jul 15;S1542-3565(21)00751-5. doi: 10.1016/j.cgh.2021.07.020.Online ahead of print.

Zobair M Younossi 1, Maria Stepanova 2, Fatema Nader 2, Rohit Loomba 3, Quentin M Anstee 4, Vlad Ratziu 5, Stephen Harrison 6, Arun J Sanyal 7, Jörn M Schattenberg 8, A Sidney Barritt 9, Mazen Noureddin 10, Martin Bonacci 11, Gail Cawkwell 11, Bruce Wong 11, Mary Rinella 12, REGENERATE Study Investigators
 
217.Pediatric nonalcoholic fatty liver disease - a changing diagnostic paradigm
 

Rom J Morphol Embryol. Oct-Dec 2020;61(4):1023-1031. doi: 10.47162/RJME.61.4.04.

Laura Mihaela Trandafir 1, Otilia Elena Frasinariu, Maria Magdalena Leon-Constantin, Stefan Chiriac, Mioara Florentina Trandafirescu, Ingrith Crenguta Miron, Alina Costina Luca, Alin Constantin Iordache, Elena Cojocaru
 
218.Conventional ultrasound for diagnosis of hepatic steatosis is better than believed
 

Z Gastroenterol. 2021 Jun 25. doi: 10.1055/a-1491-1771. Online ahead of print.

Christoph F Dietrich 1, Long Shi 2, Axel Löwe 1, Yi Dong 3, Andrej Potthoff 4, Zeno Sparchez 5, Andreas Teufel 6, Sabine Guth 7, Jonas Koch 1, Richard G Barr 8, Xin-Wu Cui 9
 
219.Defining comprehensive models of care for NAFLD
 

Nat Rev Gastroenterol Hepatol. 2021 Jun 25. doi: 10.1038/s41575-021-00477-7.Online ahead of print.

Jeffrey V Lazarus 1 2, Quentin M Anstee 3 4, Hannes Hagström 5, Kenneth Cusi 6, Helena Cortez-Pinto 7, Henry E Mark 8, Michael Roden 9 10 11, Emmanuel A Tsochatzis 12 13, Vincent Wai-Sun Wong 14, Zobair M Younossi 15, Shira Zelber-Sagi 16 17, Manuel Romero-Gómez # 18, Jörn M Schattenberg # 19
 
220.Impact of Fibrosis-4 Index Prior to COVID-19 on Outcomes in Patients at Risk of Non-alcoholic Fatty Liver Disease
 

Dig Dis Sci. 2021 Jun 26;1-7. doi: 10.1007/s10620-021-07120-0. Online ahead of print.

Mohamed A Elfeki 1 2 3, Julian Robles 1 2, Zaheer Akhtar 1 2, Fauzia Ullah 1 2, Ice Ganapathiraju 1 2, Calvin Tran 4 5, Casey Inman 4 5, Simon M Collin 6, Rossana Rosa 7
 
221.COVID-19 and pediatric fatty liver disease: Is there interplay?
 

World J Gastroenterol. 2021 Jun 14;27(22):3064-3072.doi: 10.3748/wjg.v27.i22.3064.

Anna Di Sessa 1, Francesca Lanzaro 2, Sarah Zarrilli 2, Vittorio Picone 2, Stefano Guarino 2, Emanuele Miraglia Del Giudice 2, Pierluigi Marzuillo 2
 
222.Noninvasive measure of treatment response in non-alcoholic steatohepatitis: Insights from EMMINENCE and meta-analysis
 

JGH Open. 2021 Jun 1;5(7):740-749. doi: 10.1002/jgh3.12575. eCollection 2021 Jul.

Beth A Davison 1 2, Christopher Edwards 1, Rohit Loomba 3, Stephen A Harrison 4, Gad Cotter 1 2, Naim Alkhouri 5, Gary G Koch 6, Howard C Dittrich 7
 
223.Risks and Rewards of Bariatric Surgery in Advanced Chronic Liver Diseases
 

Semin Liver Dis. 2021 Jul 9. doi: 10.1055/s-0041-1731705. Online ahead of print.

Yuly P Mendoza 1 2 3, Chiara Becchetti 1 2, Kymberly D Watt 4, Annalisa Berzigotti 1 2
 
224.Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity
 

Int J Obes (Lond). 2021 Jun 24. doi: 10.1038/s41366-021-00881-8. Online ahead of print.

Andreas Drolz # 1, Stefan Wolter # 2, Malte H Wehmeyer 3, Felix Piecha 3, Thomas Horvatits 3, Julian Schulze Zur Wiesch 3, Ansgar W Lohse 3, Oliver Mann 2, Johannes Kluwe 3
 
225.Non-alcoholic fatty liver disease in type 2 diabetes - A specific entity?
 

Liver Int. 2021 Jun;41 Suppl 1:105-111. doi: 10.1111/liv.14846.

Benjamin Schröder 1 2, Sabine Kahl 1 2, Michael Roden 1 2 3
 
226.Validation of an adipose-liver human-on-a-chip model of NAFLD for preclinical therapeutic efficacy evaluation
 

Sci Rep. 2021 Jun 23;11(1):13159. doi: 10.1038/s41598-021-92264-2.

Victoria L Slaughter 1, John W Rumsey 2, Rachel Boone 1, Duaa Malik 1, Yunqing Cai 2, Narasimhan Narasimhan Sriram 2, Christopher J Long 2, Christopher W McAleer 2, Stephen Lambert 3, Michael L Shuler 2, J J Hickman 4 5
 
227.Nonalcoholic fatty liver disease and Hepatocellular Carcinoma: Time to Bridge the Gap
 

Hepatology. 2021 Jun 23. doi: 10.1002/hep.32025. Online ahead of print.

George Cholankeril 1, Fasiha Kanwal 1 2
 
228.COVID-19 and the liver - Lessons learned
 

Liver Int. 2021 Jun;41 Suppl 1:1-8. doi: 10.1111/liv.14854.

Toni Herta 1 2, Thomas Berg 1
 
229.Anti-diabetic drugs and NASH: from current options to promising perspectives
 

Expert Opin Investig Drugs. 2021 Jul 12;1-13. doi: 10.1080/13543784.2021.1951701.Online ahead of print.

Sarra Smati 1, Clémence M Canivet 2 3, Jérôme Boursier 2 3, Bertrand Cariou 1
 
230.PPAR-?-induced Changes in Visceral Fat and Adiponectin Levels are Associated with Improvement of Steatohepatitis in Patients with NASH
 

Liver Int. 2021 Jul 5. doi: 10.1111/liv.15005. Online ahead of print.

Amalia Gastaldelli 1 2, Silvia Sabatini 2 3, Fabrizia Carli 2, Melania Gaggini 2, Fernando Bril 4, Renata Belfort-DeAguiar 5, Vincenzo Positano 6, Diana Barb 4, Sushma Kadiyala 4 7, Stephen Harrison 8, Kenneth Cusi 4 7
 
231.Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
 

Nat Med. 2021 Jul;27(7):1262-1271. doi: 10.1038/s41591-021-01425-3. Epub 2021 Jul 8.

Stephen A Harrison 1, Peter J Ruane 2, Bradley L Freilich 3, Guy Neff 4, Rashmee Patil 5, Cynthia A Behling 6, Chen Hu 7, Erica Fong 8, Brittany de Temple 8, Erik J Tillman 8, Timothy P Rolph 8, Andrew Cheng 8, Kitty Yale 9
 
232.A clinical model to predict fibrosis on liver biopsy in paediatric subjects with nonalcoholic fatty liver disease
 

Clin Obes. 2021 Jun 9;e12472. doi: 10.1111/cob.12472. Online ahead of print.

Sakil Kulkarni 1, Nadia Naz 1, Hongjie Gu 2, Janis M Stoll 1, Michael D Thompson 1 3, Brian J DeBosch 1 3 4
 
233.Copper nutrition and biochemistry and human (patho)physiology
 

Adv Food Nutr Res. 2021;96:311-364. doi: 10.1016/bs.afnr.2021.01.005. Epub 2021 Apr 12.

James F Collins 1

 
 
234.Towards collaborative management of nonalcoholic fatty liver disease (TCM-NAFLD): a 'real-world' pathway for fibrosis risk assessment in primary care
 

Intern Med J. 2021 Jun 17. doi: 10.1111/imj.15422. Online ahead of print.

Kelly L Hayward 1 2, Benjamin J McKillen 1 2, Leigh U Horsfall 1 2, Carolyn McIvor 3, Katerina Liew 3, Jo Sexton 3, Amy L Johnson 1 2, Katharine M Irvine 1 4, Patricia C Valery 1 5, Steven M McPhail 6 7, Laurence J Britton 2 8, William Rosenberg 9 10, Ingrid Weate 11, Sue Williams 12, Elizabeth E Powell 1 2
 
235.Nonalcoholic fatty liver disease is associated with a higher incidence of coeliac disease
 

Eur J Gastroenterol Hepatol. 2021 Jun 17. doi: 10.1097/MEG.0000000000002234.Online ahead of print.

Christoph Roderburg 1, Sven Loosen, Karel Kostev, Münevver Demir, Markus S Joerdens, Tom Luedde
 
236.Unraveling the Role of Hypothyroidism in Non-alcoholic Fatty Liver Disease Pathogenesis: Correlations, Conflicts, and the Current Stand
 

Cureus. 2021 May 5;13(5):e14858. doi: 10.7759/cureus.14858.

Rajvi Gor 1, Nabeel A Siddiqui 1, Ransirini Wijeratne Fernando 1, Archana Sreekantan Nair 1, Janan Illango 1, Mushrin Malik 1, Pousette Hamid 2
 
237.Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives
 

J Pers Med. 2021 Jun 2;11(6):499. doi: 10.3390/jpm11060499.

Michele Finotti 1, Maurizio Romano 1, Pasquale Auricchio 2, Michele Scopelliti 1, Marco Brizzolari 1, Ugo Grossi 1, Marco Piccino 1, Stefano Benvenuti 3, Giovanni Morana 4, Umberto Cillo 2, Giacomo Zanus 1
 
238.Association between Visceral Adipose Tissue and Non-Alcoholic Steatohepatitis Histology in Patients with Known or Suspected Non-Alcoholic Fatty Liver Disease
 

J Clin Med. 2021 Jun 10;10(12):2565. doi: 10.3390/jcm10122565.

Ilkay S Idilman 1 2, Hsien Min Low 1 3, Tolga Gidener 1, Kenneth Philbrick 1, Taofic Mounajjed 4, Jiahui Li 1, Alina M Allen 5, Meng Yin 1, Sudhakar K Venkatesh 1
 
239.Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis
 

Br J Clin Pharmacol. 2021 Jun 16. doi: 10.1111/bcp.14943. Online ahead of print.

Daniele Pastori 1, Arianna Pani 2, Arianna Di Rocco 3, Danilo Menichelli 1, Gianluca Gazzaniga 2, Alessio Farcomeni 4, Laura D'Erasmo 5, Francesco Angelico 3, Maria Del Ben 1, Francesco Baratta 1
 
240.Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease
 

J Hepatol. 2021 Jun 11;S0168-8278(21)00402-5.doi: 10.1016/j.jhep.2021.05.029.Online ahead of print.

Carolin Lackner 1, Rudolf E Stauber 2, Susan Davies 3, Helmut Denk 4, Hans Peter Dienes 5, Viviane Gnemmi 6, Maria Guido 7, Rosa Miquel 8, Valerie Paradis 9, Peter Schirmacher 10, Luigi Terracciano 11, Andrea Berghold 12, Gudrun Pregartner 12, Lukas Binder 2, Philipp Douschan 2, Florian Rainer 2, Stephan Sygulla 4, Marion Jager 13, Pierre-Emmanuel Rautou 13, Andreea Bumbu 14, Adelina Horhat 14, Ioana Rusu 15, Horia Stefanescu 14, Sönke Detlefsen 16, Aleksander Krag 17, Maja Thiele 17, Helena Cortez-Pinto 18, Christophe Moreno 19, Annette S H Gouw 20, Dina G Tiniakos 21
 
241.Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
 

Nat Rev Endocrinol. 2021 Aug;17(8):484-495. doi: 10.1038/s41574-021-00507-z.Epub 2021 Jun 15.

Daniel Ferguson 1, Brian N Finck 2
 
242.Serum Alanine Transaminase Is an Inadequate Nonalcoholic Fatty Liver Screening Test in Adolescents: Results From the National Health and Nutrition Examination Survey 2017-2018
 

Clin Pediatr (Phila). 2021 Jul;60(8):370-375. doi: 10.1177/00099228211020177.

Gary A Abrams 1, Anna M Rabil 2, Ana-Ysabel P Williams 2, Eric M Hecht 2 3 4
 
243.Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article
 

Cureus. 2021 May 20;13(5):e15141. doi: 10.7759/cureus.15141.

Haider Ghazanfar 1, Sameer D Kandhi 1, Iqra Nawaz 1, Nismat Javed 2, Minu C Abraham 1, Mohamed Farag 1, Jaydeep Mahasamudram 1, Vishwa B Patel 3, Faryal Altaf 4, Harish Patel 5
 
244.Saroglitazar for the treatment of NASH: the PPAR story goes on!
 

Hepatology. 2021 Jun 23. doi: 10.1002/hep.32024. Online ahead of print.

Sven Ma Francque 1 2 3 4
 
245.Current management of NAFLD/NASH
 

Liver Int. 2021 Jun;41 Suppl 1:89-94. doi: 10.1111/liv.14869.

Ana Carolina Cardoso 1, Claudio de Figueiredo-Mendes 2, Cristiane A Villela-Nogueira 1
 
246.New drugs for NASH
 

Liver Int. 2021 Jun;41 Suppl 1:112-118. doi: 10.1111/liv.14844.

Somaya A M Albhaisi 1, Arun J Sanyal 2
 
247.Management of NAFLD patients with advanced fibrosis
 

Liver Int. 2021 Jun;41 Suppl 1:95-104. doi: 10.1111/liv.14847.

Douglas Maya-Miles 1 2 3, Javier Ampuero 1 2 3 4, Rocío Gallego-Durán 1 2 3, Paola Dingianna 2, Manuel Romero-Gómez 1 2 3 4
 
248.Nonalcoholic fatty liver disease, circulating ketone bodies and all-cause mortality in a general population-based cohort
 

Eur J Clin Invest. 2021 Jun 13;e13627. doi: 10.1111/eci.13627. Online ahead of print.

Adrian Post 1, Erwin Garcia 2, Eline H van den Berg 3, Jose L Flores-Guerrero 1, Eke G Gruppen 1, Dion Groothof 1, Berend Daan Westenbrink 4, Margery A Connelly 2, Stephan J L Bakker 1, Robin P F Dullaart 1
 
249.Thiazolidinediones and Glucagon-like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study
 

Hepatology. 2021 Jun 15. doi: 10.1002/hep.32012. Online ahead of print.

Judith van Dalem 1 2, Johanna H M Driessen 1 2 3 4, Andrea M Burden 5, Coen D A Stehouwer 2 6, Olaf H Klungel 3, Frank de Vries 1 2 3, Martijn C G J Brouwers 2 7
 
250.Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease
 

J Intern Med. 2021 Jun 12. doi: 10.1111/joim.13343. Online ahead of print.

Hannes Hagström 1 2 3, Stergios Kechagias 4, Mattias Ekstedt 4, From the symposium: Non-Alcoholic Fatty Liver Disease (NAFLD)
 
251.Natural history of NASH
 

Liver Int. 2021 Jun;41 Suppl 1:78-82. doi: 10.1111/liv.14910.

Angelo Armandi 1, Elisabetta Bugianesi 1
 
252.Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study
 

Hepatol Commun. 2021 Feb 21;5(6):938-946. doi: 10.1002/hep4.1689. eCollection 2021 Jun.

A Sidney Barritt 1, Stephanie Watkins 2, Norman Gitlin 3, Samuel Klein 4, Anna S Lok 5, Rohit Loomba 6, Cheryl Schoen 2, K Rajender Reddy 7, Huy Ngoc Trinh 8, Andrea R Mospan 2, Miriam B Vos 9, L Michael Weiss 10, Kenneth Cusi 11, Brent A Neuschwander-Tetri 12, Arun J Sanyal 13
 
253.The Potential Protective Role of RUNX1 in Nonalcoholic Fatty Liver Disease
 

Int J Mol Sci. 2021 May 15;22(10):5239. doi: 10.3390/ijms22105239.

Laia Bertran 1, Angela Pastor 1, Marta Portillo-Carrasquer 1, Jessica Binetti 2, Carmen Aguilar 1, Salomé Martínez 3, Margarita Vives 4, Fàtima Sabench 4, José Antonio Porras 2, David Riesco 2, Daniel Del Castillo 4, Cristóbal Richart 1 2, Teresa Auguet 1 2
 
254.Animal Fat Intake Is Associated with Albuminuria in Patients with Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome
 

Nutrients. 2021 May 4;13(5):1548. doi: 10.3390/nu13051548.

Manuela Abbate 1 2, Catalina M Mascaró 1 2, Sofía Montemayor 1 2, María Barbería-Latasa 3, Miguel Casares 4, Cristina Gómez 5, Lucia Ugarriza 1 2 6, Silvia Tejada 1 2 7, Itziar Abete 7 8, María Ángeles Zulet 7 8, Antoni Sureda 1 2 7, J Alfredo Martínez 7 8 9, Josep A Tur 1 2 7
 
255.Psoriasis and Liver Damage in HIV-Infected Patients
 

Cells. 2021 May 4;10(5):1099. doi: 10.3390/cells10051099.

Carmen Busca Arenzana 1, Lucía Quintana Castanedo 2, Clara Chiloeches Fernández 2, Daniel Nieto Rodríguez 2, Pedro Herranz Pinto 2, Ana Belén Delgado Hierro 1, Antonio Olveira Martín 3, María Luisa Montes Ramírez 1
 
256.Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
 

Cancers (Basel). 2021 May 11;13(10):2305. doi: 10.3390/cancers13102305.

Gian Paolo Caviglia 1, Angelo Armandi 1, Chiara Rosso 1, Silvia Gaia 2, Serena Aneli 1 3, Emanuela Rolle 2, Maria Lorena Abate 1, Antonella Olivero 1, Aurora Nicolosi 1, Marta Guariglia 1, Davide Giuseppe Ribaldone 1, Patrizia Carucci 2, Giorgio Maria Saracco 1 2, Elisabetta Bugianesi 1 2
 
257.Role of Endocrine-Disrupting Chemicals in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: A Comprehensive Review
 

Int J Mol Sci. 2021 May 1;22(9):4807. doi: 10.3390/ijms22094807.

Raquel Cano 1, José L Pérez 1, Lissé Angarita Dávila 2, Ángel Ortega 1, Yosselin Gómez 1, Nereida Josefina Valero-Cedeño 3, Heliana Parra 1, Alexander Manzano 1, Teresa Isabel Véliz Castro 3, María P Díaz Albornoz 1, Gabriel Cano 4, Joselyn Rojas-Quintero 5, Maricarmen Chacín 6, Valmore Bermúdez 6
 
258.Surrogate scores of advanced fibrosis in NAFLD/NASH do not predict mortality in patients with medium-to-high cardiovascular risk
 

Am J Physiol Gastrointest Liver Physiol. 2021 Jun 16. doi: 10.1152/ajpgi.00058.2021.Online ahead of print.

Graciela E Delgado 1, Marcus E Kleber 1 2, Angela P Moissl 1 3 4, Babak Yazdani 1, Alexander Kusnik 5 6, Matthias P Ebert 5 6, Winfried März 1 7, Bernhard K Krämer 1 6, Alexander Lammert 1 8, Andreas Teufel 5 6
 
259.Exercise of high intensity ameliorates hepatic inflammation and the progression of NASH
 

Mol Metab. 2021 Jun 9;101270. doi: 10.1016/j.molmet.2021.101270. Online ahead of print.

Gavin Fredrickson 1, Fanta Barrow 1, Katrina Dietsche 1, Preethy Parthiban 1, Saad Khan 2, Sacha Robert 1, Maya Demirchian 1, Hailey Rhoades 1, Haiguang Wang 1, Oyedele Adeyi 3, Xavier S Revelo 4
 
260.Update on cardiovascular risk in nonalcoholic fatty liver disease
 

Curr Opin Cardiol. 2021 Jul 1;36(4):478-486.doi: 10.1097/HCO.0000000000000861.

Michael P Johnston 1, Janisha Patel 2, Christopher D Byrne 3 4
 
261.PNPLA3 Genotype, Arachidonic Acid Intake, and Unsaturated Fat Intake Influences Liver Fibrosis in Hispanic Youth with Obesity
 

Nutrients. 2021 May 12;13(5):1621. doi: 10.3390/nu13051621.

Roshonda B Jones 1, Lide Arenaza 2, Claudia Rios 1, Jasmine F Plows 1, Paige K Berger 1, Tanya L Alderete 3, Jennifer L Fogel 1, Krishna Nayak 4, Passant Mohamed 5, Darryl Hwang 5, Suzanne Palmer 5, Frank Sinatra 1, Hooman Allayee 6, Rohit Kohli 1, Michael I Goran 1
 
262.FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis
 

J Clin Med. 2021 May 29;10(11):2415. doi: 10.3390/jcm10112415.

Yasaman Vali 1, Jenny Lee 1, Jérôme Boursier 2 3, René Spijker 4 5, Joanne Verheij 6, M Julia Brosnan 7, Quentin M Anstee 8 9, Patrick M Bossuyt 1, Mohammad Hadi Zafarmand 1, On Behalf Of The Litmus Systematic Review Team
 
263.Variables associated with increased incidence of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes
 

BMJ Open Diabetes Res Care. 2021 May;9(1):e002243. doi: 10.1136/bmjdrc-2021-002243.

Sven H Loosen 1, Münevver Demir 1, Anselm Kunstein 1, Markus Jördens 1, Natalia Qvarskhava 1, Mark Luedde 1, Tom Luedde 1, Christoph Roderburg 2, Karel Kostev 3
 
264.The placebo response in randomised trials in nonalcoholic steatohepatitis simply explained
 

Clin Gastroenterol Hepatol. 2021 Jun 3;S1542-3565(21)00598-X. doi: 10.1016/j.cgh.2021.05.059.Online ahead of print.

Ian A Rowe 1, Richard Parker 2
 
265.Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease
 

J Hepatol. 2021 Jun 3;S0168-8278(21)00343-3. doi: 10.1016/j.jhep.2021.05.008.Online ahead of print.

Ramy Younes 1, Gian Paolo Caviglia 2, Olivier Govaere 3, Chiara Rosso 2, Angelo Armandi 2, Tiziana Sanavia 2, Grazia Pennisi 4, Antonio Liguori 5, Paolo Francione 6, Rocío Gallego-Durán 7, Javier Ampuero 7, Maria J Garcia Blanco 8, Rocio Aller 9, Dina Tiniakos 10, Alastair Burt 3, Ezio David 11, Fabio M Vecchio 12, Marco Maggioni 13, Daniela Cabibi 14, María Jesús Pareja 15, Marco Y W Zaki 16, Antonio Grieco 17, Anna L Fracanzani 6, Luca Valenti 18, Luca Miele 17, Piero Fariselli 2, Salvatore Petta 4, Manuel Romero-Gomez 7, Quentin M Anstee 19, Elisabetta Bugianesi 20
 
266.Circulating trimethylamine-N-oxide is associated with all-cause mortality in subjects with nonalcoholic fatty liver disease
 

 Liver Int. 2021 May 16. doi: 10.1111/liv.14963. Online ahead of print.

Jose L Flores-Guerrero 1, Adrian Post 1, Peter R van Dijk 2, Margery A Connelly 3, Erwin Garcia 3, Gerjan Navis 1, Stephan J L Bakker 1, Robin P F Dullaart 2
 
267.The role of elastography in non-alcoholic fatty liver disease
 

Minerva Gastroenterol (Torino). 2021 Jun;67(2):164-170. doi: 10.23736/S2724-5985.21.02801-4.

Antonio Liguori 1, Maria E Ainora 1, Laura Riccardi 1, Nicoletta DE Matthaeis 1, Fabrizio Pizzolante 1, Antonio Gasbarrini 1 2, Maria A Zocco 1 2, Antonio Grieco 1 2, Gianludovico Rapaccini 1 2, Luca Miele 3 2
 
268.Validation of the Dallas Steatosis Index to Predict Nonalcoholic Fatty Liver Disease in the UK Biobank Population
 

Clin Gastroenterol Hepatol. 2021 May 25;S1542-3565(21)00573-5.doi: 10.1016/j.cgh.2021.05.035. Online ahead of print.

Scott McHenry 1, Yikyung Park 2, Nicholas O Davidson 3
 
269.Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes
 

PLoS One. 2021 Jun 2;16(6):e0251449. doi: 10.1371/journal.pone.0251449. eCollection 2021.

Kristin Alexandra Dayton 1, Fernando Bril 2 3, Diana Barb 2, Jinping Lai 4, Srilaxmi Kalavalapalli 2, Kenneth Cusi 2 3
 
270.Step by Step: Managing the Complications of Cirrhosis
 

Hepat Med. 2021 May 25;13:45-57.doi: 10.2147/HMER.S278032. eCollection 2021.

Irene Perez 1, Fabian J Bolte 1, William Bigelow 1, Zachary Dickson 2, Neeral L Shah 2
 
271.Week 4 Liver Fat Reduction on MRI as an Early Predictor of Treatment Response in Participants with Nonalcoholic Steatohepatitis
 

Radiology. 2021 Jun 1;204325. doi: 10.1148/radiol.2021204325. Online ahead of print.

Hanyu Jiang 1, Hubert C Chen 1, Kyle J Lafata 1, Mustafa R Bashir 1
 
272.Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis
 

Cochrane Database Syst Rev. 2021 Jun 11;6:CD013156.doi: 10.1002/14651858.CD013156.pub2.

Elena Buzzetti 1, Audrey Linden 2, Lawrence Mj Best 2, Angela M Madden 3, Danielle Roberts 2, Thomas J G Chase 4, Suzanne C Freeman 5, Nicola J Cooper 5, Alex J Sutton 5, Dominic Fritche 6, Elisabeth Jane Milne 7, Kathy Wright 8, Chavdar S Pavlov 9, Brian R Davidson 2, Emmanuel Tsochatzis 1, Kurinchi Selvan Gurusamy 2 9
 
273.Infections at the nexus of metabolic-associated fatty liver disease
 

Arch Toxicol. 2021 May 24;1-19. doi: 10.1007/s00204-021-03069-1.Online ahead of print.

Joost Boeckmans 1 2, Matthias Rombaut 3, Thomas Demuyser 4 5, Baptist Declerck 4, Denis Piérard 4, Vera Rogiers 3, Joery De Kock 3, Luc Waumans 6, Koen Magerman 6 7, Reinoud Cartuyvels 6, Jean-Luc Rummens 6, Robim M Rodrigues # 8, Tamara Vanhaecke # 3
 
274.Hepatocellular Carcinoma in Patients Without Cirrhosis: The Fibrosis Stage Distribution, Characteristics and Survival
 

Dig Dis Sci. 2021 May 23. doi: 10.1007/s10620-021-07048-5. Online ahead of print.

Kanokwan Pinyopornpanish 1 2, Wael Al-Yaman 3, Srinivasan Dasarathy 3 4, Carlos Romero-Marrero 3, Arthur McCullough 3 4
 
275.The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007-2017
 

Hepatol Commun. 2021 Jan 14;5(5):749-759. doi: 10.1002/hep4.1673. eCollection 2021 May.

James M Paik 1, Pegah Golabi 1, Youssef Younossi 2, Nazaneen Saleh 1, Annan Nhyira 1, Zobair M Younossi 1 3
 
276.Discovery of novel modulators for the PPARa (peroxisome proliferator activated receptor a): Potential therapies for nonalcoholic fatty liver disease
 

Bioorg Med Chem. 2021 May 1;41:116193. doi: 10.1016/j.bmc.2021.116193. Online ahead of print.

 

Donna D Yu 1, Gregg Van Citters 2, Hongzhi Li 3, Brian M Stoltz 4, Barry M Forman 3
 
277.The Patient's Perspective in Cirrhosis: Unmet Supportive Care Needs Differ by Disease Severity, Etiology, and Age
 

Hepatol Commun. 2021 Feb 6;5(5):891-905. doi: 10.1002/hep4.1681. eCollection 2021 May.

Patricia C Valery 1, Christina M Bernardes 1, Benjamin Mckillen 2 3, Samath Amarasena 4, Katherine A Stuart 2, Gunter Hartel 1, Paul J Clark 2 5, Richard Skoien 4, Tony Rahman 6, Leigh Horsfall 2 3, Kelly Hayward 2 3, Rohit Gupta 6, Andrew Lee 5, Leshni Pillay 7, Elizabeth E Powell 2 3
 
278.Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting
 

PLoS One. 2021 May 21;16(5):e0251741. doi: 10.1371/journal.pone.0251741. eCollection 2021.

Stephen E Congly 1 2, Abdel Aziz Shaheen 1 3, Mark G Swain 1
 
279.Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial
 

Hepatol Commun. 2021 Feb 5;5(5):786-797. doi: 10.1002/hep4.1680. eCollection 2021 May.

Samer Gawrieh 1, Laura A Wilson 2, Katherine P Yates 2, Oscar W Cummings 3, Eduardo Vilar-Gomez 1, Veeral Ajmera 4, Kris V Kowdley 5, William M Rosenberg 6, James Tonascia 2, Naga Chalasani 1
 
280.Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease
 

World J Gastroenterol. 2021 May 21;27(19):2281-2298.doi: 10.3748/wjg.v27.i19.2281.

Lukas Hartl 1, Joshua Elias 2, Gerhard Prager 3, Thomas Reiberger 1, Lukas W Unger 4
 
281.coreNASH: Multi-stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment
 

Hepatol Commun. 2021 Feb 12;5(5):774-785. doi: 10.1002/hep4.1678. eCollection 2021 May.

Elizabeth Clearfield 1, Veronica Miller 2, Joseph Nadglowski 3, Katherine Barradas 2, Jennifer Al Naber 1, Arun J Sanyal 4, Brent A Neuschwander-Tetri 5, Donna A Messner 1, coreNASH Panel

Collaborators,

Collaborators

  • coreNASH Panel: 

William Baldyga, Maria-Magdalena Balp, Catherine Brun-Strang, Robyn Carson, Wayne Eskridge, Kurinchi Gurusamy, Lars Hansen, Morten Hansen, Katy Harrison, Andras Harsanyi, Anders Hvelplund, Zoltán Kaló, Marko Korenjak, E J Milne, Euan McLeod, Michelle Mocarski, Joachim Musaeus, Fady Ntanios, Mazen Noureddin, Daniel Ollendorf, Jan Oscarsson, Stephen Rossi, Vlad Ratziu, Yaron Rotman, Leonardo Ruiz-Casas, Lewis Sandy, Jörn M Schattenberg, Mohammad Shadab Siddiqui, Gregory Steinberg, Ethan Weiss, Keith White, José Willemse, Kathy Wright, Michael Zemel
 
282.Non-alcoholic fatty liver diseases: current challenges and future directions
 

Ann Transl Med. 2021 Apr;9(8):726. doi: 10.21037/atm-20-3760.

Elke Roeb 1
 
283.Metabolic dysfunction-associated fatty liver disease (MAFLD) - rather a bystander than a driver of mortality
 

J Clin Endocrinol Metab. 2021 May 13;dgab339. doi: 10.1210/clinem/dgab339.Online ahead of print.

Georg Semmler 1 2, Sarah Wernly 1, Sebastian Bachmayer 1, Isabella Leitner 1, Bernhard Wernly 3, Matthias Egger 1, Lena Schwenoha 1, Leonora Datz 1, Lorenz Balcar 1 2, Marie Semmler 1, Felix Stickel 4, David Niederseer 5, Elmar Aigner 6, Christian Datz 1
 
284.Obesity Management of Liver Transplant Waitlist Candidates and Recipients
 

Clin Liver Dis. 2021 Feb;25(1):1-18. doi: 10.1016/j.cld.2020.08.001.Epub 2020 Oct 12.

Danielle Brandman 1
 
285.Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
 

Liver Int. 2021 May 12. doi: 10.1111/liv.14943. Online ahead of print.

Patrizia Burra 1, Debora Bizzaro 1, Anna Gonta 1, Sarah Shalaby 1, Martina Gambato 1, Maria Cristina Morelli 2, Silvia Trapani 3, Annarosa Floreani 4 5, Fabio Marra 6, Maurizia Rossana Brunetto 7, Gloria Taliani 8, Erica Villa 9, Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF)
 
286.The GLP-1 Receptor Agonist Semaglutide for the Treatment of Nonalcoholic Steatohepatitis
 

Hepatology. 2021 May 6. doi: 10.1002/hep.31886. Online ahead of print.

Laura E Dichtel 1
 
287.Quantifying the progression of non-alcoholic fatty liver disease in human biomimetic liver microphysiology systems with fluorescent protein biosensors
 

Exp Biol Med (Maywood). 2021 May 6;15353702211009228. doi: 10.1177/15353702211009228.Online ahead of print.

Manush Saydmohammed 1, Anupma Jha 1, Vineet Mahajan 1, Dillon Gavlock 1, Tong Ying Shun 1, Richard DeBiasio 1, Daniel Lefever 1, Xiang Li 1, Celeste Reese 1, Erin E Kershaw 2, Vijay Yechoor 2, Jaideep Behari 3 4, Alejandro Soto-Gutierrez 5 6, Larry Vernetti 1 7, Andrew Stern 1 7, Albert Gough 1 7, Mark T Miedel 1 7, D Lansing Taylor 1 6 7
 
288.New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease
 

Semin Liver Dis. 2021 Jan;41(1):87-102. doi: 10.1055/s-0040-1719174. Epub 2021 Jan 14.

Phillipp Hartmann 1 2, Bernd Schnabl 2 3
 
289.Efficacy of Weight Reduction on Pediatric Nonalcoholic Fatty Liver Disease: Opportunities to Improve Treatment Outcomes Through Pharmacotherapy
 

Front Endocrinol (Lausanne). 2021 Apr 13;12:663351. doi: 10.3389/fendo.2021.663351.eCollection 2021.

Chance S Friesen 1, Chelsea Hosey-Cojocari 2, Sherwin S Chan 2 3, Iván L Csanaky 2 3 4, Jonathan B Wagner 2 3, Brooke R Sweeney 2 3 5, Alec Friesen 1, Jason D Fraser 2 3, Valentina Shakhnovich 2 3 4 5
 
290.The interplay of Western diet and binge drinking on the onset, progression, and outlook of liver disease
 

Nutr Rev. 2021 May 9;nuab031. doi: 10.1093/nutrit/nuab031. Online ahead of print.

R Chris Skinner 1, Joel A Hagaman 1
 
291.The Emerging Role of B Cells in the Pathogenesis of NAFLD
 

Hepatology. 2021 May 7. doi: 10.1002/hep.31889. Online ahead of print.

Fanta Barrow 1, Saad Khan 2, Haiguang Wang 1, Xavier S Revelo 1 3
 
292.Physical activity is associated with reduced risk of liver disease in the prospective UK Biobank cohort
 

JHEP Rep. 2021 Mar 2;3(3):100263. doi: 10.1016/j.jhepr.2021.100263. eCollection 2021 Jun.

Carolin V Schneider 1, Inuk Zandvakili 2, Christoph A Thaiss 3 4 5, Kai Markus Schneider 3 4 5
 
293.The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD
 

Genes (Basel). 2021 Apr 26;12(5):645. doi: 10.3390/genes12050645.

Emmanuel D Dixon 1, Alexander D Nardo 1, Thierry Claudel 1, Michael Trauner 1
 
294.Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH- the State of the Art
 

Hepatology. 2021 Apr 30. doi: 10.1002/hep.31869. Online ahead of print.

Amreen M Dinani 1, Kris V Kowdley 2, Mazen Noureddin 3
 
295.Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment
 

Front Med (Lausanne). 2021 Apr 14;8:615978. doi: 10.3389/fmed.2021.615978.eCollection 2021.

Leen J M Heyens 1 2 3, Dana Busschots 1 2, Ger H Koek 2 4, Geert Robaeys 1 3 5, Sven Francque 6 7
 
296.Mechanisms and disease consequences of nonalcoholic fatty liver disease
 

Cell. 2021 May 13;184(10):2537-2564. doi: 10.1016/j.cell.2021.04.015.

Rohit Loomba 1, Scott L Friedman 2, Gerald I Shulman 3
 
297.Functional characterization of organoids derived from irreversibly damaged NASH patient liver
 

Hepatology. 2021 Apr 26. doi: 10.1002/hep.31857. Online ahead of print.

Sarah McCarron 1, Brooke Bathon 1, Donna M Conlon 1, Deepti Abbey 1, Daniel J Rader 1, Katerina Gawronski 2, Christopher D Brown 2, Kim M Olthoff 3, Abraham Shaked 3, Tobias D Raabe 1
 
298.Free Fatty Acid Receptors as Mediators and Therapeutic Targets in Liver Disease
 

Front Physiol. 2021 Apr 7;12:656441. doi: 10.3389/fphys.2021.656441.eCollection 2021.

Jordan D Secor 1, Scott C Fligor 1, Savas T Tsikis 1, Lumeng J Yu 1, Mark Puder 1
 
299.Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases
 

JHEP Rep. 2021 Feb 19;3(3):100255. doi: 10.1016/j.jhepr.2021.100255. eCollection 2021 Jun.

Arun J Sanyal 1, Lei Ling 2, Ulrich Beuers 3, Alex M DePaoli 2, Hsiao D Lieu 2, Stephen A Harrison 4 5, Gideon M Hirschfield 6
 
300.Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial
 

JHEP Rep. 2021 Feb 17;3(3):100256. doi: 10.1016/j.jhepr.2021.100256. eCollection 2021 Jun.

Magnus Holmer 1 2, Catarina Lindqvist 3 4, Sven Petersson 5 6, John Moshtaghi-Svensson 7, Veronika Tillander 8, Torkel B Brismar 6 9, Hannes Hagström 1 2 10, Per Stål 1 2
 
301.Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease
 

Liver Int. 2021 Apr 25. doi: 10.1111/liv.14899. Online ahead of print.

Sonja Lang 1 2, Anna Martin 1, Xinlian Zhang 3, Fedja Farowski 4 5 6, Hilmar Wisplinghoff 7 8 9, Maria J G T Vehreschild 4 5 6, Marcin Krawczyk 10 11, Angela Nowag 7 9, Anne Kretzschmar 7, Claus Scholz 7, Philipp Kasper 1, Christoph Roderburg 12, Raphael Mohr 13, Frank Lammert 10 14, Frank Tacke 13, Bernd Schnabl 2 15, Tobias Goeser 1, Hans-Michael Steffen 1, Münevver Demir 13
 
302.Allele Specific Variation at APOE Increases Non-alcoholic Fatty Liver Disease and Obesity but Decreases Risk of Alzheimer's Disease and Myocardial Infarction
 

Hum Mol Genet. 2021 Apr 15;ddab096. doi: 10.1093/hmg/ddab096. Online ahead of print.

Nicholette D Palmer 1, Bratati Kahali 2 3, Annapurna Kuppa 3, Yanhua Chen 3, Xiaomeng Du 3, Mary F Feitosa 4, Lawrence F Bielak 5, Jeffrey R O'Connell 6, Solomon K Musani 7, Xiuqing Guo 8, Albert V Smith 9, Kathleen A Ryan 6, Gudny Eirksdottir 9, Matthew A Allison 10, Donald W Bowden 1, Matthew J Budoff 11, J Jeffrey Carr 12, Yii-Der I Chen 8, Kent D Taylor 8, Adolfo Correa 7, Breland F Crudup 7, Brian Halligan 3, Jian Yang 13, Sharon L R Kardia 5, Lenore J Launer 14, Yi-Ping Fu 15 16, Thomas H Mosley 7, Jill M Norris 17, James G Terry 12, Christopher J O'Donnell 1, Jerome I Rotter 8, Lynne E Wagenknecht 18, Vilmundur Gudnason 9 19, Michael A Province 4, Patricia A Peyser 5, Elizabeth K Speliotes 3
 
303.Definite and indeterminate NASH share similar clinical features and prognosis: a longitudinal study of 1893 biopsy-proven NAFLD subjects
 

Liver Int. 2021 Apr 25. doi: 10.1111/liv.14898. Online ahead of print.

Javier Ampuero 1 2 3, Rocío Aller 4, Rocío Gallego-Durán 2 3, Javier Crespo 5, Javier Abad 6, Águeda González-Rodríguez 7, Judith Gómez-Camarero 8, Joan Caballería 3 9, Oreste Lo Iacono 10, Luis Ibañez 3 11, Javier García-Samaniego 3 12, Rosa Martín-Mateos 3 13, Rubén Francés 3 14, Conrado Fernández-Rodríguez 15, Moisés Diago 16, Germán Soriano 3 17, Raúl J Andrade 3 18, Raquel Latorre 19, Francisco Jorquera 3 20, Rosa María Morillas 3 21, Desamparados Escudero 22, Pamela Estévez 23, Manuel Hernández Guerra 24, Salvador Augustín 25, María Jesús Pareja-Megia 26, Jesús M Banales 3 27, Patricia Aspichueta 28, Salvador Benlloch 3 29, José Miguel Rosales 30, Javier Salmerón 31, Juan Turnes 32, Manuel Romero Gómez 1 2 3, HEPAmet Registry
 
304.Non-alcoholic fatty liver disease
 

Lancet. 2021 Apr 21;S0140-6736(20)32511-3.doi: 10.1016/S0140-6736(20)32511-3. Online ahead of print.

Elizabeth E Powell 1, Vincent Wai-Sun Wong 2, Mary Rinella 3
 
305.Clinical Management of Nonalcoholic Steatohepatitis (NASH) With the Use of Thiazolidinediones and the Additive Effect of Thiazolidinediones and a GLP-1 Agonist: Case Series
 

Cureus. 2021 Mar 24;13(3):e14082. doi: 10.7759/cureus.14082.

Valentina Rojas Ortiz 1, Jonathan Nieves 2, Enrique C Fernandez 3
 
306.Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
 

Int J Mol Sci. 2021 Apr 17;22(8):4173. doi: 10.3390/ijms22084173.

Miriam Longo 1 2, Erika Paolini 1 3, Marica Meroni 1, Paola Dongiovanni 1
 
307.The importance of glycemic equipoise in NASH
 

Hepatology. 2021 Apr 26. doi: 10.1002/hep.31866. Online ahead of print.

Alina M Allen 1, Brent A Neuschwander-Tetri 2
 
308.Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis
 

J Hepatol. 2021 Apr 19;S0168-8278(21)00248-8. doi: 10.1016/j.jhep.2021.04.013.Online ahead of print.

Geraldine J Ooi 1, Peter J Meikle 2, Kevin Huynh 2, Arul Earnest 3, Stuart K Roberts 4, William Kemp 4, Benjamin L Parker 5, Wendy Brown 1, Paul Burton 6, Matthew J Watt 7
 
309.Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH
 

Hepatol Commun. 2021 Jan 4;5(4):573-588. doi: 10.1002/hep4.1657. eCollection 2021 Apr.

Stephen A Harrison 1 2, Mustafa Bashir 3, Sam E Moussa 4, Kevin McCarty 5, Juan Pablo Frias 6, Rebecca Taub 7, Naim Alkhouri 8

Affiliations expand
 
310.Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
 

Hepatology. 2021 Apr 3. doi: 10.1002/hep.31845. Online ahead of print.

Tracey G Simon 1 2 3, Bjorn Roelstraete 4, Rajani Sharma 5 6, Hamed Khalili 1 2 3, Hannes Hagström 7 8, Jonas F Ludvigsson 4 9 10 11

 
 
311.Cholesterol Accumulation as a Driver of Hepatic Inflammation Under Translational Dietary Conditions Can Be Attenuated by a Multicomponent Medicine
 

Front Endocrinol (Lausanne). 2021 Mar 18;12:601160. doi: 10.3389/fendo.2021.601160.eCollection 2021.

Andrea M Mueller 1, Robert Kleemann 2 3, Eveline Gart 2 4, Wim van Duyvenvoorde 2, Lars Verschuren 5, Martien Caspers 5, Aswin Menke 2, Natascha Krömmelbein 1, Kanita Salic 2, Yvonne Burmeister 1, Bernd Seilheimer 1, Martine C Morrison 2 4
 
312.The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD)
 

PLoS One. 2021 Apr 6;16(4):e0249614. doi: 10.1371/journal.pone.0249614. eCollection 2021.

Roberta D'Ambrosio 1, Irene Campi 2, Marco Maggioni 3, Riccardo Perbellini 1, Enza Giammona 4, Roberta Stucchi 4, Marta Borghi 1, Elisabetta Degasperi 1, Annalisa De Silvestri 5, Luca Persani 2 6, Laura Fugazzola 2 7, Pietro Lampertico 1 7
 
313.Allele Specific Variation at APOE Increases Non-alcoholic Fatty Liver Disease and Obesity but Decreases Risk of Alzheimer's Disease and Myocardial Infarction
 

Hum Mol Genet. 2021 Apr 15;ddab096. doi: 10.1093/hmg/ddab096. Online ahead of print.

Nicholette D Palmer 1, Bratati Kahali 2 3, Annapurna Kuppa 3, Yanhua Chen 3, Xiaomeng Du 3, Mary F Feitosa 4, Lawrence F Bielak 5, Jeffrey R O'Connell 6, Solomon K Musani 7, Xiuqing Guo 8, Albert V Smith 9, Kathleen A Ryan 6, Gudny Eirksdottir 9, Matthew A Allison 10, Donald W Bowden 1, Matthew J Budoff 11, J Jeffrey Carr 12, Yii-Der I Chen 8, Kent D Taylor 8, Adolfo Correa 7, Breland F Crudup 7, Brian Halligan 3, Jian Yang 13, Sharon L R Kardia 5, Lenore J Launer 14, Yi-Ping Fu 15 16, Thomas H Mosley 7, Jill M Norris 17, James G Terry 12, Christopher J O'Donnell 1, Jerome I Rotter 8, Lynne E Wagenknecht 18, Vilmundur Gudnason 9 19, Michael A Province 4, Patricia A Peyser 5, Elizabeth K Speliotes 3
 
314.Saroglitazar, a PPAR-a/? Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double-Blind Phase 2 Trial
 

Hepatology. 2021 Apr 2. doi: 10.1002/hep.31843. Online ahead of print.

Samer Gawrieh 1, Mazen Noureddin 2, Nicole Loo 3, Rizwana Mohseni 4, Vivek Awasty 5, Kenneth Cusi 6, Kris V Kowdley 7, Michelle Lai 8, Eugene Schiff 9, Deven Parmar 10, Pankaj Patel 11, Naga Chalasani 1
 
315.MAFLD in Obese Children: A Challenging Definition
 

Children (Basel). 2021 Mar 23;8(3):247. doi: 10.3390/children8030247.

Anna Di Sessa 1, Stefano Guarino 1, Giuseppina Rosaria Umano 1, Mattia Arenella 1, Salvatore Alfiero 1, Gaetano Quaranta 1, Emanuele Miraglia Del Giudice 1, Pierluigi Marzuillo 1
 
316.Role of Angiogenesis in the Pathogenesis of NAFLD
 

J Clin Med. 2021 Mar 24;10(7):1338. doi: 10.3390/jcm10071338.

Lin Lei 1, Haquima Ei Mourabit 1, Chantal Housset 1 2, Axelle Cadoret 1, Sara Lemoinne 1 2
 
317.PNPLA3 Single Nucleotide Polymorphism Prevalence and Association with Liver Disease in a Diverse Cohort of Persons Living with HIV
 

Biology (Basel). 2021 Mar 21;10(3):242. doi: 10.3390/biology10030242.

Kenneth E Sherman 1, Susan D Rouster 1, Heidi Meeds 1, Javier Tamargo 2, Jun Chen 3, Richard Ehman 3, Marianna Baum 2
 
318.Comparison of Ketogenic Diets with and without Ketone Salts versus a Low-Fat Diet: Liver Fat Responses in Overweight Adults
 

Nutrients. 2021 Mar 17;13(3):966. doi: 10.3390/nu13030966.

Christopher D Crabtree 1, Madison L Kackley 1, Alexandru Buga 1, Brandon Fell 1, Richard A LaFountain 1, Parker N Hyde 1, Teryn N Sapper 1, William J Kraemer 1, Debbie Scandling 2, Orlando P Simonetti 2 3, Jeff S Volek 1
 
319.PNPLA3 and SERPINA1 Variants Are Associated with Severity of Fatty Liver Disease at First Referral to a Tertiary Center
 

J Pers Med. 2021 Mar 1;11(3):165. doi: 10.3390/jpm11030165.

Georg Semmler 1 2 3, Lorenz Balcar 1 2, Hannes Oberkofler 4, Stephan Zandanell 1, Michael Strasser 1, David Niederseer 5, Alexandra Feldman 1, Felix Stickel 6, Pavel Strnad 7, Christian Datz 3, Bernhard Paulweber 1, Elmar Aigner 1
 
320.Association of obstructive sleep apnea with non-alcoholic fatty liver disease in patients with obesity: an observational study
 

Eat Weight Disord. 2021 Apr 3;1-9. doi: 10.1007/s40519-021-01182-9. Online ahead of print.

Silvia Bettini 1, Roberto Serra 2, Roberto Fabris 2, Chiara Dal Prà 2, Francesca Favaretto 3 2, Francesca Dassie 3, Claudio Duso 3, Roberto Vettor 3 2, Luca Busetto 3 2
 
321.Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort
 

PLoS One. 2021 Apr 1;16(4):e0249491. doi: 10.1371/journal.pone.0249491. eCollection 2021.

Cayden Beyer 1, Chloe Hutton 1, Anneli Andersson 1, Kento Imajo 2, Atsushi Nakajima 2, Dustin Kiker 3, Rajarshi Banerjee 1, Andrea Dennis 1
 
322.The Diabetes Syndrome - A Collection of Conditions with Common, Interrelated Pathophysiologic Mechanisms
 

Int J Gen Med. 2021 Mar 18;14:923-936. doi: 10.2147/IJGM.S305156. eCollection 2021.

Amy W Rachfal 1, Struan F A Grant 2 3 4, Stanley S Schwartz 5 6
 
323.Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update
 

J Exp Pharmacol. 2021 Mar 18;13:329-338. doi: 10.2147/JEP.S265286.eCollection 2021.

Tsipora M Huisman 1, Douglas T Dieterich 1, Scott L Friedman 1
 
324.Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes
 

Front Endocrinol (Lausanne). 2021 Mar 4;12:642432. doi: 10.3389/fendo.2021.642432.eCollection 2021.

Jacqueline Bayliss 1, Geraldine J Ooi 2, William De Nardo 1, Yazmin Johari Halim Shah 2, Magdalene K Montgomery 1, Catriona McLean 3, William Kemp 4, Stuart K Roberts 4, Wendy A Brown 2, Paul R Burton 2, Matthew J Watt 1
 
325.The prevalence of metabolic associated fatty liver detected by FibroScan® in women with gestational diabetes in a multiethnic population
 

Diabetes Res Clin Pract. 2021 Mar 17;174:108757. doi: 10.1016/j.diabres.2021.108757.Online ahead of print.

Difei Deng 1, Jacob George 2, Dharmintra Pasupathy 3, N Wah Cheung 4
 
326.Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives
 

Curr Obes Rep. 2021 Mar 22. doi: 10.1007/s13679-021-00431-3.Online ahead of print.

Christina-Maria Flessa 1 2, Ioannis Kyrou 2 3 4, Narjes Nasiri-Ansari 1, Gregory Kaltsas 5, Athanasios G Papavassiliou 1, Eva Kassi 6 7, Harpal S Randeva 8 9
 
327.Alternative Etiologies of Liver Disease in Children With Suspected NAFLD
 

Pediatrics. 2021 Mar 30;147(4):e2020009829. doi: 10.1542/peds.2020-009829.Online ahead of print.

Toshifumi Yodoshi 1, Sarah Orkin 1, Ana Catalina Arce-Clachar 1 2, Kristin Bramlage 1, Stavra A Xanthakos 1 2, Pamela L Valentino 3, Marialena Mouzaki 4 2
 
328.LI-RADS v2018 major criteria: Do hepatocellular carcinomas in non-alcoholic steatohepatitis differ from those in virus-induced chronic liver disease on MRI?
 

Eur J Radiol. 2021 Mar 11;138:109651. doi: 10.1016/j.ejrad.2021.109651. Online ahead of print.

Maxime Barat 1, Thi Thuy Linh Nguyen 2, Clémence Hollande 3, Jean-Baptiste Coty 4, Christine Hoeffel 5, Benoit Terris 6, Anthony Dohan 4, Vincent Mallet 3, Stanislas Pol 3, Philippe Soyer 4
 
329.NASH limits anti-tumour surveillance in immunotherapy-treated HCC
 

Nature. 2021 Mar 24. doi: 10.1038/s41586-021-03362-0. Online ahead of print.

Dominik Pfister 1 2, Nicolás Gonzalo Núñez 3, Roser Pinyol 4, Olivier Govaere 5, Matthias Pinter 6 7, Marta Szydlowska 1, Revant Gupta 8 9, Mengjie Qiu 10, Aleksandra Deczkowska 11, Assaf Weiner 11, Florian Müller 1, Ankit Sinha 12 13, Ekaterina Friebel 3, Thomas Engleitner 14 15 16, Daniela Lenggenhager 17, Anja Moncsek 18, Danijela Heide 1, Kristin Stirm 1, Jan Kosla 1, Eleni Kotsiliti 1, Valentina Leone 1 19, Michael Dudek 20, Suhail Yousuf 10, Donato Inverso 21 22, Indrabahadur Singh 1 23, Ana Teijeiro 24, Florian Castet 4, Carla Montironi 4, Philipp K Haber 25, Dina Tiniakos 5 26, Pierre Bedossa 5, Simon Cockell 27, Ramy Younes 5 28, Michele Vacca 29, Fabio Marra 30, Jörn M Schattenberg 31, Michael Allison 32, Elisabetta Bugianesi 28, Vlad Ratziu 33, Tiziana Pressiani 34, Antonio D'Alessio 34, Nicola Personeni 34 35, Lorenza Rimassa 34 35, Ann K Daly 5, Bernhard Scheiner 6 7, Katharina Pomej 6 7, Martha M Kirstein 36 37, Arndt Vogel 36, Markus Peck-Radosavljevic 38, Florian Hucke 38, Fabian Finkelmeier 39, Oliver Waidmann 39, Jörg Trojan 39, Kornelius Schulze 40, Henning Wege 40, Sandra Koch 41, Arndt Weinmann 41, Marco Bueter 42, Fabian Rössler 42, Alexander Siebenhüner 43, Sara De Dosso 44, Jan-Philipp Mallm 45, Viktor Umansky 46 47, Manfred Jugold 48, Tom Luedde 49, Andrea Schietinger 50 51, Peter Schirmacher 52, Brinda Emu 1, Hellmut G Augustin 21 22, Adrian Billeter 53, Beat Müller-Stich 53, Hiroto Kikuchi 54, Dan G Duda 54, Fabian Kütting 55, Dirk-Thomas Waldschmidt 55, Matthias Philip Ebert 56, Nuh Rahbari 57, Henrik E Mei 58, Axel Ronald Schulz 58, Marc Ringelhan 59 60 61, Nisar Malek 62, Stephan Spahn 62, Michael Bitzer 62, Marina Ruiz de Galarreta 25 63, Amaia Lujambio 25 63 64, Jean-Francois Dufour 65 66, Thomas U Marron 25 67, Ahmed Kaseb 68, Masatoshi Kudo 69, Yi-Hsiang Huang 70 71, Nabil Djouder 24, Katharina Wolter 72 73, Lars Zender 72 73 74, Parice N Marche 75 76, Thomas Decaens 75 76 77, David J Pinato 78 79, Roland Rad 14 15 16, Joachim C Mertens 18, Achim Weber 17 80, Kristian Unger 19, Felix Meissner 12, Susanne Roth 10, Zuzana Macek Jilkova 75 76 78, Manfred Claassen 8 9, Quentin M Anstee 5 81, Ido Amit 11, Percy Knolle 20, Burkhard Becher 3, Josep M Llovet 82 83 84, Mathias Heikenwalder 85

Affiliations collapse
 
330.Bariatric Surgery Reduces Cancer Risk in Adults with Nonalcoholic Fatty Liver Disease and Severe Obesity
 

Gastroenterology. 2021 Mar 17;S0016-5085(21)00529-1. doi: 10.1053/j.gastro.2021.03.021.Online ahead of print.

Vinod K Rustgi 1, You Li 2, Kapil Gupta 2, Carlos D Minacapelli 2, Abhishek Bhurwal 2, Carolyn Catalano 2, Mohamed I Elsaid 2
 
331.The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk
 

Curr Diab Rep. 2021 Mar 19;21(5):15. doi: 10.1007/s11892-021-01383-7.

Cyrielle Caussy 1, Adrien Aubin 2, Rohit Loomba 3 4 5
 
332.Sex differences in NAFLD: estrogen influence on the liver-adipose tissue crosstalk
 

Antioxid Redox Signal. 2021 Mar 19. doi: 10.1089/ars.2021.0044. Online ahead of print.

Andrea Morán-Costoya 1 2, Ana María Proenza 1 3 4, Magdalena Gianotti 5 3 6, Isabel Lladó 1 3 7, Adamo Valle 1 3 8
 
333.Ten Thousand Points of Light - Heterogeneity Among the Stars of NASH Fibrosis
 

Hepatology. 2021 Mar 16.doi: 10.1002/hep.31807. Online ahead of print.

James Carter 1, Shuang Wang 1, Scott L Friedman 1
 
334.The clinical impact of cirrhosis on the postoperative outcomes of patients undergoing bariatric surgery: propensity score-matched analysis of 2011-2017 US hospitals
 

Expert Rev Gastroenterol Hepatol. 2021 Mar 12. doi: 10.1080/17474124.2021.1902803.Online ahead of print.

David Uihwan Lee 1, Gregory Hongyuan Fan 1, David Jeffrey Hastie 1, Elyse Ann Addonizio 1, Vibhav Narayan Prakasam 1, Ryan Richard Ahern 1, Kristen Jin Seog 1, Raffi Karagozian 1
 
335.Awareness of non-alcoholic steatohepatitis and treatment guidelines: What are physicians telling us?
 

World J Hepatol. 2021 Feb 27;13(2):233-241. doi: 10.4254/wjh.v13.i2.233.

David Hermanus Wessels 1, Zeil Rosenberg 2
 
336.Coronary artery disease and non-alcoholic fatty liver disease: Clinical correlation using computed tomography coronary calcium scans
 

JGH Open. 2021 Feb 19;5(3):390-395. doi: 10.1002/jgh3.12509. eCollection 2021 Mar.

Richard S Kirby 1, Dina Halegoua-DeMarzio 2
 
337.Increased adipose tissue fibrogenesis, not impaired expandability, is associated with nonalcoholic fatty liver disease
 

Hepatology. 2021 Mar 20. doi: 10.1002/hep.31822. Online ahead of print.

Joseph W Beals 1, Gordon I Smith 1, Mahalakshmi Shankaran 2, Anja Fuchs 3, George G Schweitzer 1, Jun Yoshino 1, Tyler Field 2, Marcy Matthews 2, Edna Nyangau 2, Darya Morozov 4, Bettina Mittendorfer 1, Marc K Hellerstein 2, Samuel Klein 1
 
338.European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?
 

JHEP Rep. 2021 Jan 21;3(2):100234. doi: 10.1016/j.jhepr.2021.100234. eCollection 2021 Apr.

Jeffrey V Lazarus 1, Adam Palayew 2, Patrizia Carrieri 3, Mattias Ekstedt 4, Giulio Marchesini 5, Katja Novak 6, Vlad Ratziu 7, Manuel Romero-Gómez 8, Frank Tacke 9, Shira Zelber-Sagi 10, Helena Cortez-Pinto 11, Quentin M Anstee 12 13
 
339.Treatment candidacy for pharmacologic therapies for NASH
 

Clin Gastroenterol Hepatol. 2021 Mar 9;S1542-3565(21)00228-7.doi: 10.1016/j.cgh.2021.03.005. Online ahead of print.

Ian A Rowe 1, Vincent Wai-Sun Wong 2, Rohit Loomba 3
 
340.The Impact of Macronutrient Intake on Non-alcoholic Fatty Liver Disease (NAFLD): Too Much Fat, Too Much Carbohydrate, or Just Too Many Calories?
 

Front Nutr. 2021 Feb 16;8:640557. doi: 10.3389/fnut.2021.640557. eCollection 2021.

Theresa Hydes 1 2, Uazman Alam 1 2, Daniel J Cuthbertson 1 2
 
341.Treatments for NAFLD: State of Art
 

Int J Mol Sci. 2021 Feb 26;22(5):2350. doi: 10.3390/ijms22052350.

Alessandro Mantovani 1, Andrea Dalbeni 2
 
342.The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis
 

Contemp Clin Trials. 2021 Feb 28;106335. doi: 10.1016/j.cct.2021.106335. Online ahead of print.

Manal F Abdelmalek 1, Edgar D Charles 2, Arun J Sanyal 3, Stephen A Harrison 4, Brent A Neuschwander-Tetri 5, Zachary Goodman 6, Richard A Ehman 7, Morten Karsdal 8, Atsushi Nakajima 9, Shuyan Du 10, Giridhar S Tirucherai 10, George H Klinger 10, Johanna Mora 10, Masayuki Yamaguchi 10, Diane E Shevell 10, Rohit Loomba 11
 
343.Artificial Intelligence in NASH Histology: Human Teaches a Machine for the Machine to help Humans
 

Hepatology. 2021 Feb 26. doi: 10.1002/hep.31777. Online ahead of print.

Mazen Noureddin 1 2 3 4
 
344.Case-finding strategies in non-alcoholic fatty liver disease
 

JHEP Rep. 2020 Dec 5;3(2):100219. doi: 10.1016/j.jhepr.2020.100219.eCollection 2021 Apr.

Jerome Boursier 1 2, Emmanuel A Tsochatzis 3 4
 
345.Evaluation of a primary to secondary care referral pathway and novel nurse-led one-stop clinic for patients with suspected non-alcoholic fatty liver disease
 

Frontline Gastroenterol. 2020 Apr 7;12(2):102-107. doi: 10.1136/flgastro-2019-101304.eCollection 2021.

Andrew J Fowell 1, Kirsty Fancey 1, Karen Gamble 1, Kelly Bicknell 2, Joanna K Dowman 1, Paul Howden 3, Richard J Aspinall 1
 
346.Non-alcoholic fatty liver disease and cognitive function in middle-aged adults: the CARDIA study
 

BMC Gastroenterol. 2021 Mar 2;21(1):96. doi: 10.1186/s12876-021-01681-0.

Yariv Gerber 1 2 3, Lisa B VanWagner 4, Kristine Yaffe 5, James G Terry 6, Jamal S Rana 7 5, Jared P Reis 8, Stephen Sidney 7
 
347.Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease
 

Obes Surg. 2021 Feb 22. doi: 10.1007/s11695-020-04996-1. Online ahead of print.

Saleh A Alqahtani 1 2 3, Pegah Golabi 4 5, James M Paik 4 5, Brian Lam 4, Amir H Moazez 5, Hazem A Elariny 5, Zachary Goodman 4, Zobair M Younossi 6 7
 
348.TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism
 

Front Endocrinol (Lausanne). 2021 Jan 29;11:613639.doi: 10.3389/fendo.2020.613639. eCollection 2020.

Christopher R Shepard 1
 
349.Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis
 

Front Endocrinol (Lausanne). 2021 Jan 27;11:575843. doi: 10.3389/fendo.2020.575843.eCollection 2020.

Andrea Dennis 1, Matt D Kelly 1, Carolina Fernandes 1, Sofia Mouchti 1, Jonathan A Fallowfield 2, Gideon Hirschfield 3, Michael Pavlides 4 5 6, Stephen Harrison 4 7, Manu V Chakravarthy 8, Rajarshi Banerjee 1, Arun Sanyal 9
 
350.Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions
 

Clin Ther. 2021 Feb 11;S0149-2918(21)00048-5. doi: 10.1016/j.clinthera.2021.01.021.Online ahead of print.

Patrick Campbell 1, Allison Symonds 2, A Sidney Barritt 4th 3
 
351.Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT
 

ESC Heart Fail. 2021 Feb 14. doi: 10.1002/ehf2.13250. Online ahead of print.

Anthony E Peters 1, Ambarish Pandey 2, Colby Ayers 2, Kara Wegermann 3, Robert W McGarrah 1, Justin L Grodin 2, Manal F Abdelmalek 3, Tarek Bekfani 4, Vanessa L Blumer 1, Anna Mae Diehl 3, Cynthia A Moylan 3, Marat Fudim 1
 
352.Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
 

Clin Ther. 2021 Feb 10;S0149-2918(21)00016-3. doi: 10.1016/j.clinthera.2021.01.012.Online ahead of print.

Shannon Kogachi 1, Mazen Noureddin 2
 
353.A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis
 

J Hepatol. 2021 Feb 10;S0168-8278(21)00099-4. doi: 10.1016/j.jhep.2021.01.047.Online ahead of print.

Stephen A Harrison 1, Mustafa R Bashir 2, Kyoung-Jin Lee 3, Jennifer Shim-Lopez 3, Jonathan Lee 3, Brandee Wagner 3, Nicholas D Smith 3, Hubert C Chen 4, Eric J Lawitz 5
 
354.Insulin resistance dysregulates CYP7B1 leading to oxysterol accumulation: a pathway for NAFL to NASH transition
 

J Lipid Res. 2020 Dec;61(12):1629-1644. doi: 10.1194/jlr.RA120000924. Epub 2021 Jan 12.

Genta Kakiyama 1, Dalila Marques 2, Rebecca Martin 3, Hajime Takei 4, Daniel Rodriguez-Agudo 2, Sandra A LaSalle 5, Taishi Hashiguchi 6, Xiaoying Liu 7, Richard Green 7, Sandra Erickson 8, Gregorio Gil 9, Michael Fuchs 2, Mitsuyoshi Suzuki 10, Tsuyoshi Murai 11, Hiroshi Nittono 4, Phillip B Hylemon 12, Huiping Zhou 12, William M Pandak 13
 
355.Editorial: Emerging metabolic and transcriptomic signature of PNPLA3 associated NASH
 

Hepatology. 2021 Feb 5. doi: 10.1002/hep.31735. Online ahead of print.

Debanjan Dhar 1, Rohit Loomba 1 2 3
 
356.Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition?
 

J Clin Med. 2021 Jan 31;10(3):492. doi: 10.3390/jcm10030492.

Amedeo Lonardo 1
 
357.Tumor Incidence in Patients with Non-Alcoholic Fatty Liver Disease
 

Dtsch Arztebl Int. 2020 Oct 23;117(43):719-724. doi: 10.3238/arztebl.2020.0719.

Yvonne Huber 1, Christian Labenz, Maurice Michel, Marcus-A Wörns, Peter R Galle, Karel Kostev, Jörn M Schattenberg
 
358.Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM
 

BMJ Open Gastroenterol. 2021 Feb;8(1):e000572. doi: 10.1136/bmjgast-2020-000572.

Kelly Lee Hayward 1 2, Amy L Johnson 1 2, Leigh U Horsfall 1 2, Chris Moser 3, Patricia C Valery # 1 4, Elizabeth E Powell # 5 2
 
359.NAFLD-related HCC
 

Adv Cancer Res. 2021;149:143-169. doi: 10.1016/bs.acr.2020.11.001. Epub 2021 Jan 21.

Bubu A Banini 1, Arun J Sanyal 2
 
360.A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH
 

Hepatology. 2021 Feb 11. doi: 10.1002/hep.31750. Online ahead of print.

Amaro Taylor-Weiner 1, Harsha Pokkalla 1, Ling Han 2, Catherine Jia 2, Ryan Huss 2, Chuhan Chung 2, Hunter Elliott 1, Benjamin Glass 1, Kishalve Pethia 1, Oscar Carrasco-Zevallos 1, Chinmay Shukla 1, Urmila Khettry 3, Robert Najarian 4, Ross Taliano 5, G Mani Subramanian 2, Robert P Myers 2, Ilan Wapinski 1, Aditya Khosla 1, Murray Resnick 1 5, Michael C Montalto 1, Quentin M Anstee 6, Vincent Wai-Sun Wong 7, Michael Trauner 8, Eric J Lawitz 9, Stephen A Harrison 10, Takeshi Okanoue 11, Manuel Romero-Gomez 12, Zachary Goodman 13 14, Rohit Loomba 15, Andrew H Beck 1, Zobair M Younossi 13 14
 
361.Human Nonalcoholic Steatohepatitis on a Chip
 

Hepatol Commun. 2020 Nov 29;5(2):217-233. doi: 10.1002/hep4.1647. eCollection 2021 Feb.

May S Freag 1 2, Bumseok Namgung 1 2, Maria E Reyna Fernandez 1 2, Ermanno Gherardi 3, Shiladitya Sengupta 1 2 4, Hae Lin Jang 1
 
362.Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting
 

Hepatol Commun. 2020 Oct 31;5(2):158-167. doi: 10.1002/hep4.1618.eCollection 2021 Feb.

Joana Vieira Barbosa 1 2, Michelle Lai 1